{"gene":"ACE2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2000,"finding":"ACE2 was identified as the first human homologue of ACE; it is a zinc metalloprotease with a single HEXXH active site that functions exclusively as a carboxypeptidase, cleaving the C-terminal leucine from angiotensin I to generate angiotensin 1-9, and is not inhibited by classical ACE inhibitors (captopril, lisinopril). The gene maps to chromosome Xp22 and encodes an 805-amino-acid type I transmembrane glycoprotein secreted as a soluble form by cleavage N-terminal to the transmembrane domain.","method":"Recombinant protein expression in CHO cells, in vitro enzymatic assay, substrate cleavage characterization, northern blotting, immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic activity with substrate characterization, independently confirmed by a second discovery paper the same year","pmids":["10924499"],"is_preprint":false},{"year":2000,"finding":"ACE2 converts angiotensin I to angiotensin 1-9 and also cleaves angiotensin II; recombinant ACE2 is secreted from transfected cells by cleavage N-terminal to the transmembrane domain. ACE2 transcripts were detected specifically in heart, kidney, and testis, and immunohistochemistry localized ACE2 protein predominantly to coronary/intrarenal vascular endothelium and renal tubular epithelium.","method":"cDNA library cloning, recombinant expression, in vitro enzymatic assay, northern blot, immunohistochemistry","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic activity plus direct localization, foundational discovery paper","pmids":["10969042"],"is_preprint":false},{"year":2002,"finding":"Comprehensive substrate profiling of purified ACE2 against 126 biological peptides revealed that ACE2 hydrolyzes angiotensin II (kcat/Km = 1.9×10⁶ M⁻¹s⁻¹), apelin-13 (kcat/Km = 2.1×10⁶ M⁻¹s⁻¹), and dynorphin A 1-13 (kcat/Km = 3.1×10⁶ M⁻¹s⁻¹) with highest efficiency; in each case only the C-terminal residue is removed. Catalytic efficiency for angiotensin II is 400-fold higher than for angiotensin I. ACE2 does not hydrolyze bradykinin.","method":"Protein purification, LC-MS substrate screening panel (126 peptides), kinetic assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro biochemical characterization with kinetic constants across broad substrate panel","pmids":["11815627"],"is_preprint":false},{"year":2002,"finding":"Targeted disruption of ACE2 in mice causes severe cardiac contractility defect with increased angiotensin II levels and upregulation of hypoxia-induced genes in the heart; genetic ablation of ACE on the ACE2-null background completely rescues the cardiac phenotype, placing ACE2 functionally downstream/counter-regulatory to ACE in the renin-angiotensin system in vivo. ACE2 mRNA and protein are markedly reduced in three different rat hypertension models, and the ace2 locus maps to a hypertension QTL on the X chromosome.","method":"Knockout mouse generation, cardiac function measurements, genetic epistasis (ACE/ACE2 double knockout), QTL mapping, mRNA/protein expression in rat models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo KO with defined cardiac phenotype plus ACE/ACE2 double-KO epistasis rescue, foundational functional study","pmids":["12075344"],"is_preprint":false},{"year":2003,"finding":"ACE2 was identified as the functional receptor for SARS-CoV: the S1 domain of the SARS-CoV spike protein binds ACE2 efficiently; soluble ACE2 (but not soluble ACE1) blocks S1-domain association with Vero E6 cells; 293T cells transfected with ACE2 form syncytia with S-protein-expressing cells and support SARS-CoV replication; anti-ACE2 antibody (but not anti-ACE1) blocks viral replication.","method":"Receptor identification from permissive cell lysates, transfection assay, pseudovirus/syncytia assay, antibody blockade, viral replication assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal functional assays (binding, syncytia, replication, antibody blockade), highly replicated foundational paper","pmids":["14647384"],"is_preprint":false},{"year":2004,"finding":"ACE2 protein is expressed on the surface of lung alveolar epithelial cells and enterocytes of the small intestine, and in arterial/venous endothelial cells and smooth muscle cells of all organs examined, establishing tissue tropism relevant to SARS-CoV pathogenesis.","method":"Immunohistochemistry on multiple human organ samples","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — direct protein localization across multiple organs in human tissue, highly cited foundational localization study","pmids":["15141377"],"is_preprint":false},{"year":2005,"finding":"ACE2 protects mice from severe acute lung injury: ACE2-deficient mice show dramatically worsened ARDS (induced by acid aspiration or sepsis), while recombinant ACE2 administration rescues lung function. The pathway involves ACE2 inactivating angiotensin II; angiotensin II acting via AT1a receptor promotes lung edema and injury, while ACE2 and AT2 receptor are protective. ACE-knockout mice show markedly improved lung injury.","method":"ACE2 knockout and recombinant ACE2 rescue in mouse ARDS models (acid aspiration, sepsis), lung function measurements, genetic epistasis with ACE KO and receptor KOs","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo KO + recombinant protein rescue + genetic epistasis across multiple models","pmids":["16001071"],"is_preprint":false},{"year":2005,"finding":"ACE2 activity and mRNA increase in the border/infarct zone after myocardial infarction in rats (day 3 and day 28) and in viable myocardium by day 28; ACE2 protein localizes to macrophages, vascular endothelium, smooth muscle, and cardiomyocytes post-MI. Ramipril (ACE inhibitor) attenuates cardiac hypertrophy and inhibits ACE but does not suppress elevated ACE2 mRNA post-MI. ACE2 immunoreactivity also increases in failing human hearts.","method":"Rat MI model, quantitative RT-PCR, immunohistochemistry, in vitro autoradiography, enzymatic activity assays","journal":"European heart journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (activity assay, IHC, qPCR) in animal model plus human tissue confirmation","pmids":["15671045"],"is_preprint":false},{"year":2005,"finding":"Crystal structure (2.9 Å) of the SARS-CoV RBD bound to the peptidase domain of human ACE2 revealed that the RBD presents a gently concave surface cradling the N-terminal lobe of the ACE2 peptidase domain; atomic details clarify residues enabling cross-species infection and human-to-human transmission.","method":"X-ray crystallography at 2.9 Å resolution","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional annotation","pmids":["16166518"],"is_preprint":false},{"year":2008,"finding":"Angiotensin II downregulates ACE2 mRNA and activity in rat vascular smooth muscle cells via the MAP kinase (ERK1/2) pathway; angiotensin-(1-7) prevents this downregulation by activating a MAP kinase phosphatase (effect blocked by tyrosine and serine-threonine phosphatase inhibitors). ANG II treatment increases ERK1/2 activity, which is reduced by ANG-(1-7) pretreatment. This MAP kinase/phosphatase axis is the primary molecular mechanism for ACE2 regulation.","method":"Cell-based assays in rat aortic VSMCs, ACE2 activity and mRNA measurement, ERK1/2 kinase assay, pharmacological inhibitors (PD98059, sodium vanadate, okadaic acid), receptor antagonist blockade","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological interventions establishing signaling pathway, mechanistically rigorous","pmids":["18768926"],"is_preprint":false},{"year":2011,"finding":"ACE2 acts as an amino acid transporter chaperone: its collectrin-like domain (transmembrane domain) is required for surface expression of neutral amino acid transporter B0AT1 in the intestine, linking ACE2 to amino acid absorption and the pathogenesis of Hartnup disorder.","method":"Review synthesizing functional and genetic studies on ACE2/collectrin/B0AT1 transporter complexes in kidney and intestine","journal":"Channels (Austin, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 — review citing established experimental data on transporter association, consistent with structural studies","pmids":["21814048"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structures of full-length human ACE2 in complex with the neutral amino acid transporter B0AT1 (with and without SARS-CoV-2 RBD) at 2.9 Å resolution revealed: (1) ACE2-B0AT1 assembles as a dimer of heterodimers, with ACE2's collectrin-like domain mediating homodimerization; (2) the SARS-CoV-2 RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues.","method":"Cryo-electron microscopy at 2.9 Å overall resolution (3.5 Å at ACE2-RBD interface)","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — high-resolution cryo-EM structure with direct functional validation of binding interface","pmids":["32132184"],"is_preprint":false},{"year":2020,"finding":"SARS-CoV-2 uses ACE2 as its entry receptor and requires TMPRSS2 for spike protein priming; a clinically approved TMPRSS2 inhibitor (camostat mesylate) blocks SARS-CoV-2 entry. Convalescent SARS-CoV-1 sera cross-neutralize SARS-CoV-2 spike-driven entry.","method":"Pseudovirus entry assay, authentic virus infection, TMPRSS2 inhibitor treatment, antibody neutralization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution assays with pseudovirus and authentic virus, pharmacological inhibition, highly replicated","pmids":["32142651"],"is_preprint":false},{"year":2020,"finding":"2019-nCoV (SARS-CoV-2) uses the same cell entry receptor ACE2 as SARS-CoV, confirmed by demonstrating that the isolated virus can be neutralized by sera from SARS patients and that the new virus shares 79.6% sequence identity with SARS-CoV.","method":"Virus isolation, whole-genome sequencing, neutralization assay with convalescent sera","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct virological characterization with neutralization confirmation","pmids":["32015507"],"is_preprint":false},{"year":2020,"finding":"Crystal structure of SARS-CoV-2 RBD bound to human ACE2 peptidase domain at atomic resolution showed the overall binding mode is nearly identical to SARS-CoV RBD-ACE2, but key substitutions in SARS-CoV-2 RBD strengthen the interaction and increase ACE2-binding affinity compared to SARS-CoV.","method":"X-ray crystallography, surface plasmon resonance binding affinity measurements","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus biophysical binding measurement","pmids":["32225176"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structure of SARS-CoV-2 spike trimer demonstrated that the receptor-binding domain (RBD) binds ACE2 with higher affinity than SARS-CoV spike; in the predominant prefusion state, one of three RBDs is rotated 'up' in a receptor-accessible conformation.","method":"Cryo-EM at 3.5 Å, biolayer interferometry binding assay","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with biophysical binding validation","pmids":["32075877"],"is_preprint":false},{"year":2020,"finding":"SARS-CoV-2 spike protein harbors a furin cleavage site at the S1/S2 boundary (absent in SARS-CoV) that is processed during biogenesis; SARS-CoV-2 S and SARS-CoV S RBDs bind human ACE2 with similar affinities. SARS-CoV polyclonal antibodies potently inhibit SARS-CoV-2 spike-mediated cell entry.","method":"Cryo-EM structure determination, cell-cell fusion assay, pseudovirus entry assay, flow cytometry binding, antibody neutralization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure plus functional entry assays","pmids":["32155444"],"is_preprint":false},{"year":2020,"finding":"SARS-CoV-2 RBD has higher ACE2-binding affinity than SARS-CoV RBD, but the intact SARS-CoV-2 spike has comparable or lower ACE2 affinity than SARS-CoV spike (due to less-exposed RBD). SARS-CoV-2 cell entry is pre-activated by proprotein convertase furin, reducing its dependence on target cell proteases. SARS-CoV-2 enters cells primarily through endocytosis and requires PIKfyve, TPC2, and cathepsin L.","method":"Biochemical binding assays, pseudovirus entry assays, furin inhibitor treatment, endocytosis pathway inhibitors","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — multiple biochemical and cell-based assays with pharmacological dissection of entry pathway","pmids":["32376634"],"is_preprint":false},{"year":2020,"finding":"ACE2 is an interferon-stimulated gene (ISG) in human airway epithelial cells: type I and type III interferon treatment induces ACE2 expression in vitro, and ACE2 is upregulated in vivo during viral infections. ACE2 and TMPRSS2 are co-expressed in lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.","method":"Single-cell RNA sequencing (human, NHP, mouse), in vitro interferon stimulation assays, in vivo viral infection transcriptomics","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — direct functional interferon stimulation experiment plus multi-species scRNA-seq validation","pmids":["32413319"],"is_preprint":false},{"year":2020,"finding":"ACE2 receptor protein robustly localizes within the motile cilia of airway epithelial cells of the upper respiratory tract, representing the likely initial subcellular site of SARS-CoV-2 entry. ACE inhibitor or ARB use does not increase ciliary ACE2 expression.","method":"Multiplexed immunofluorescence (CODEX) on banked human nasal and pulmonary tissue, immunohistochemistry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — direct protein localization by multiplexed imaging on human tissue with functional implication for viral entry","pmids":["33116139"],"is_preprint":false},{"year":2020,"finding":"EZH2-mediated H3K27me3 at the ACE2 promoter region inhibits ACE2 expression: EZH2 knockout in human embryonic stem cells significantly increased ACE2 expression, ChIP-seq confirmed decreased H3K27me3 and increased H3K27ac at the ACE2 promoter upon EZH2 knockout, and reduction of H3K27me3 (but not H3K4/9/36me3) upregulated Ace2 in a mouse germ cell line.","method":"EZH2 knockout in hESCs, RNA-seq, ChIP-seq, qPCR in mouse GC-2 cells with histone methylation manipulation","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus ChIP-seq chromatin mapping with orthogonal cell line validation","pmids":["32291076"],"is_preprint":false},{"year":2021,"finding":"ACE2 interacts directly with the PDZ scaffold protein NHERF1 through its C-terminal PDZ-recognition motif; both NHERF1 PDZ domains bind ACE2. Disruption of NHERF1 PDZ motifs or ACE2 PDZ recognition sequence eliminates interaction. NHERF1 tethers ACE2 at the cell membrane and facilitates SARS-CoV-2 internalization: elimination of the ACE2 C-terminal PDZ-binding motif decreased ACE2 membrane residence and reduced pseudotyped virus entry.","method":"Proximity ligation assay (PLA) in human lung/intestine cells, mutagenesis of PDZ motifs, pseudotyped virus entry assay, ACE2 membrane localization quantification","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 — direct interaction validated by PLA at endogenous levels plus functional mutagenesis of binding interface","pmids":["34189428"],"is_preprint":false},{"year":2022,"finding":"SARS-CoV-2 infection down-regulates ACE2 in vivo (animal model) and in cultured cells by inducing clathrin- and AP2-dependent endocytosis leading to lysosomal degradation. ACE2 knockdown cells exhibit similar transcriptional changes to SARS-CoV-2-S-treated cells (activated cytokine signaling). A soluble ACE2 fragment with stronger SARS-CoV-2 S-binding efficiently blocks ACE2 downregulation and viral infection.","method":"In vivo infection model, cell-based endocytosis assays with clathrin/AP2 knockdown, lysosomal degradation inhibitors, ACE2 knockdown transcriptomics, pseudovirus neutralization with soluble ACE2 fragment","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic dissection of endocytosis pathway with genetic knockdowns and pharmacological inhibitors in vivo and in vitro","pmids":["36287912"],"is_preprint":false},{"year":2022,"finding":"ACE2 pathway (ACE2 cleaving Ang II to generate Ang-(1-7) acting via Mas1 receptor) is a critical regulator of thermogenesis and energy expenditure: Ace2 and Mas1 knockout mice display impaired thermogenesis; cold stimulation increases ACE2 and Ang-(1-7) in brown adipose tissue (BAT); ACE2 overexpression or Ang-(1-7) infusion ameliorates impaired thermogenesis in obese mice; mechanistically, the ACE2/Ang-(1-7)/Mas1 axis activates Akt/FoxO1 and PKA signaling, inducing UCP1 and activating mitochondrial function and white adipose browning.","method":"ACE2 and Mas1 knockout mice, BAT transplantation, ACE2 overexpression, Ang-(1-7) infusion, high-fat diet and Lepr-mutant obese models, UCP1/PKA/Akt pathway analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (KO, overexpression, BAT transplantation) with mechanistic pathway dissection","pmids":["35014608"],"is_preprint":false},{"year":2022,"finding":"ACE2 endogenous receptors are present as monomers in the plasma membrane at densities of 1–2 receptors/μm², and binding of trimeric SARS-CoV-2 spike proteins does not induce ACE2 oligomerization; a single spike protein interaction with a monomeric ACE2 is sufficient for viral infection.","method":"Direct stochastic optical reconstruction microscopy (dSTORM), single-molecule localization, VSV pseudotyped virus infection assays","journal":"Angewandte Chemie (International ed. in English)","confidence":"High","confidence_rationale":"Tier 1–2 — super-resolution imaging of endogenous ACE2 with functional infection validation","pmids":["36971081"],"is_preprint":false},{"year":2022,"finding":"STAT3 binds the ACE2 promoter and controls ACE2 expression in bronchial epithelial cells stimulated with IL-6; inhibition of STAT3-ACE2 promoter interaction by the compound 6-OAP suppresses ACE2 transcription and blocks SARS-CoV-2 pseudovirus entry into lung epithelial cells.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, qPCR, western blot, SARS-CoV-2 pseudovirus entry assay, in vivo mouse lung ACE2 measurement","journal":"Acta pharmacologica Sinica","confidence":"High","confidence_rationale":"Tier 2 — ChIP of STAT3 at ACE2 promoter plus functional entry assay, replicated in vivo","pmids":["35468992"],"is_preprint":false},{"year":2023,"finding":"Nedd4-2 is the first E3 ubiquitin ligase identified to promote ACE2 ubiquitination, leading to ACE2 downregulation in neurogenic hypertension. Mutation of lysine residues in the ACE2 C-terminal domain generates a ubiquitination-resistant ACE2 (ACE2-5R) with increased activity and resistance to Ang-II-mediated degradation. Expression of ACE2-5R in the bed nucleus of the stria terminalis enhanced GABAergic input to the paraventricular nucleus and reduced hypertension, establishing ACE2's role on GABAergic neurons in sympathetic regulation.","method":"Bioinformatics + proteomics identification of E3 ligase, in vitro gain/loss-of-function, ACE2 mutagenesis (ACE2-5R), optogenetics, blood pressure telemetry, AAV-mediated brain expression, capillary western analysis","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — proteomics-identified interaction, mutagenesis, multiple in vivo functional measurements with mechanistic pathway placement","pmids":["37161607"],"is_preprint":false},{"year":2013,"finding":"A live bat SL-CoV (WIV1) closely related to SARS-CoV was isolated from bat fecal samples and demonstrated to use ACE2 from humans, civets, and Chinese horseshoe bats for cell entry, confirming ACE2 as the functional receptor for bat progenitor viruses of SARS-CoV.","method":"Virus isolation in Vero E6 cells, whole-genome sequencing, pseudovirus entry assay with ACE2 orthologs","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — live virus isolation plus functional receptor usage assay with multiple ACE2 orthologs","pmids":["24172901"],"is_preprint":false},{"year":2021,"finding":"ACE2 inhibits breast cancer angiogenesis by suppressing the VEGFa/VEGFR2/ERK pathway: ACE2 expression in breast cancer cells downregulates VEGFa and inactivates phosphorylation of VEGFR2, MEK1/2, and ERK1/2 in endothelial cells, inhibiting tube formation, migration, and neo-angiogenesis in a zebrafish model.","method":"Transwell migration assay, tube formation assay, wound healing assay, western blot (phospho-VEGFR2/MEK/ERK), qPCR, zebrafish xenograft model","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple functional assays with pathway analysis, but single lab study","pmids":["31023337"],"is_preprint":false},{"year":2022,"finding":"ACE2 maintains intestinal barrier integrity and prevents diabetic retinopathy through intestinal MasR activation: genetic overexpression of intestinal ACE2 in Akita (T1D) mice preserved gut barrier integrity, reduced systemic inflammation, improved hyperglycemia via GSK-3β/c-Myc-mediated decrease in intestinal glucose transporter expression, and delayed/reversed diabetic retinopathy.","method":"Transgenic intestinal ACE2 overexpression (Vil-Cre.hAce2KI-Akita mice), Lactobacillus-expressed ACE2 probiotic, intestinal permeability assays, ocular endpoint measurements, western blot pathway analysis","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — two independent genetic/pharmacological interventions with mechanistic pathway identification (MasR/GSK-3β/c-Myc)","pmids":["36448480"],"is_preprint":false},{"year":2021,"finding":"Auto-antibodies against ACE2 develop in the majority (81–93%) of patients after SARS-CoV-2 infection; plasma from these patients inhibits exogenous ACE2 enzymatic activity and is associated with lower soluble ACE2 activity in plasma, consistent with autoantibody-mediated ACE2 inhibition contributing to post-acute sequelae.","method":"ELISA for ACE2 antibodies, fluorometric ACE2 enzymatic activity assay with patient plasma, soluble ACE2 protein measurement","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct enzymatic inhibition assay with patient plasma plus ELISA, single study","pmids":["34478478"],"is_preprint":false},{"year":2021,"finding":"Deep mutational scanning of all possible single amino-acid substitutions in the SARS-CoV-2 RBD identified mutations that enhance or reduce ACE2 binding affinity; most mutations are deleterious, but a subset (including at ACE2 interface residues conserved across sarbecoviruses) enhance ACE2 affinity. Constrained surface regions were identified as potential vaccine/therapeutic targets.","method":"Deep mutational scanning (yeast display), high-throughput ACE2 binding measurements across all single-amino-acid RBD variants","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with quantitative binding measurements across full RBD sequence space","pmids":["32841599"],"is_preprint":false},{"year":2022,"finding":"CRISPR loss-of-function screens identified cell-type-specific regulators of ACE2 surface abundance: in HuH7 cells, SMAD4, EP300, PIAS1, and BAMBI regulate ACE2 at the mRNA level and influence SARS-CoV-2 susceptibility; in Calu-3 lung cells, KDM6A, MOGS, GPAA1, and UGP2 are distinct ACE2 modifiers, demonstrating cell-type specificity of ACE2 regulatory networks.","method":"High-throughput CRISPR screens for ACE2 surface abundance, individual KO validation, SARS-CoV-2 infection susceptibility assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — genome-scale CRISPR screening with individual gene validation plus functional viral infection readout","pmids":["35231079"],"is_preprint":false},{"year":2021,"finding":"LiGaMD simulations captured spontaneous binding/unbinding of the ACE2 inhibitor MLN-4760 and showed that unliganded ACE2 samples distinct Open, Partially Open, Closed, and Fully Closed conformations; upon ligand binding, the conformational ensemble shifts toward the Closed state (as seen in the X-ray structure), suggesting a conformational selection mechanism for ligand recognition by ACE2.","method":"All-atom ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations, microsecond timescale, validated against X-ray experimental structure","journal":"The journal of physical chemistry letters","confidence":"Low","confidence_rationale":"Tier 4 — computational simulation, no experimental validation of conformational states","pmids":["33999630"],"is_preprint":false},{"year":2025,"finding":"Cryo-EM structure captured an ACE2-induced early fusion intermediate conformation (E-FIC) of SARS-CoV-2 spike in which HR1 in S2 has ejected while S1 remains attached; this E-FIC transitions to the late fusion intermediate after S2' cleavage. An E-FIC-targeted dual-functional antiviral protein (AL5E) was designed that inactivated ACE2-using coronaviruses and protected animals.","method":"Cryo-EM structure determination of ACE2-induced spike E-FIC, recombinant antiviral protein design (AL5E), in vitro and in vivo antiviral efficacy assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure of intermediate conformation with functional antiviral validation in vivo","pmids":["39889696"],"is_preprint":false}],"current_model":"ACE2 is a zinc-dependent type I transmembrane carboxypeptidase (805 aa, gene at Xp22) that constitutively degrades angiotensin II to the vasodilatory Ang-(1-7) and angiotensin I to Ang 1-9, counterbalancing ACE/angiotensin II signaling in the renin-angiotensin system; it is essential for cardiac function in vivo (loss causes contractility defects rescued by ACE deletion), protects against acute lung injury via angiotensin II inactivation, regulates thermogenesis through Ang-(1-7)/Mas1/PKA/Akt signaling in brown adipose tissue, chaperones intestinal B0AT1 amino acid transporter, is transcriptionally regulated by EZH2-mediated H3K27me3 and by STAT3, and is subject to Nedd4-2-mediated ubiquitination and proteasomal degradation, as well as SARS-CoV-2-induced clathrin/AP2-dependent lysosomal degradation; structurally, full-length ACE2 dimerizes via its collectrin-like domain and binds SARS-CoV-2 and SARS-CoV spike RBDs as monomers at the extracellular peptidase domain, making it the primary functional entry receptor for these coronaviruses, a role stabilized by interaction with the PDZ scaffold protein NHERF1 at the membrane."},"narrative":{"teleology":[{"year":2000,"claim":"Identification of ACE2 as a novel carboxypeptidase homologous to ACE resolved whether a second angiotensin-converting enzyme existed and established its distinct substrate specificity and insensitivity to classical ACE inhibitors.","evidence":"Recombinant expression in CHO cells with enzymatic assays, northern blotting, and immunohistochemistry across two independent discovery papers","pmids":["10924499","10969042"],"confidence":"High","gaps":["Physiological role in vivo not yet determined","Full substrate repertoire unknown","Mechanism of ectodomain shedding uncharacterized"]},{"year":2002,"claim":"Comprehensive substrate profiling and kinetic analysis revealed that ACE2 preferentially degrades angiotensin II (400-fold over Ang I), along with apelin-13 and dynorphin A, establishing it as a dedicated angiotensin II inactivator rather than a general ACE-like enzyme.","evidence":"LC-MS screening of 126 peptides with purified ACE2 and kinetic constant determination","pmids":["11815627"],"confidence":"High","gaps":["In vivo relevance of non-angiotensin substrates (apelin, dynorphin) not tested","Structural basis of substrate selectivity undetermined"]},{"year":2002,"claim":"Genetic ablation of ACE2 in mice demonstrated its essential role in cardiac function and placed it as the in vivo counter-regulatory enzyme to ACE, since the severe cardiac contractility defect of ACE2 knockouts was fully rescued by concurrent ACE deletion.","evidence":"ACE2 knockout mice with cardiac phenotyping, ACE/ACE2 double-knockout epistasis, QTL mapping in rat hypertension models","pmids":["12075344"],"confidence":"High","gaps":["Downstream mediators of cardiac protection not fully delineated","Contribution of non-angiotensin substrates to cardiac phenotype unknown"]},{"year":2003,"claim":"The discovery that ACE2 serves as the functional receptor for SARS-CoV fundamentally expanded its biology beyond the renin–angiotensin system, showing that the viral spike S1 domain co-opts ACE2 for cell entry.","evidence":"Receptor identification from permissive cell lysates, syncytia formation, pseudovirus entry, antibody blockade, and viral replication in ACE2-transfected 293T cells","pmids":["14647384"],"confidence":"High","gaps":["Structural details of spike–ACE2 interface unknown","Whether ACE2 enzymatic activity is altered by spike binding not addressed"]},{"year":2005,"claim":"Structural and functional studies established the atomic basis of SARS-CoV RBD–ACE2 recognition and demonstrated ACE2's protective role against acute lung injury through angiotensin II inactivation, unifying its enzymatic and receptor biology in lung pathology.","evidence":"Crystal structure of SARS-CoV RBD–ACE2 at 2.9 Å; ACE2-knockout mice with worsened ARDS rescued by recombinant ACE2 and by genetic ACE deletion","pmids":["16166518","16001071"],"confidence":"High","gaps":["Therapeutic window for recombinant ACE2 in human ARDS not defined","Whether spike binding impairs ACE2 catalytic activity in vivo not resolved"]},{"year":2008,"claim":"Identification of the ERK1/2 MAP kinase pathway as the mechanism by which angiotensin II downregulates ACE2—and Ang-(1-7) opposes this via MAP kinase phosphatase activation—revealed a feedback loop governing ACE2 expression.","evidence":"Pharmacological dissection (ERK inhibitors, phosphatase inhibitors) in rat aortic VSMCs with ACE2 mRNA and activity readouts","pmids":["18768926"],"confidence":"High","gaps":["Identity of the specific MAP kinase phosphatase not determined","Relevance in human cells not confirmed"]},{"year":2011,"claim":"Recognition that ACE2's collectrin-like domain chaperones the neutral amino acid transporter B0AT1 to the intestinal surface linked ACE2 to amino acid absorption and Hartnup disorder, revealing a non-catalytic structural function.","evidence":"Review synthesizing functional and genetic data on ACE2/collectrin/B0AT1 transport complexes","pmids":["21814048"],"confidence":"Medium","gaps":["Direct structural visualization of the ACE2–B0AT1 complex not yet obtained","Whether ACE2 enzymatic activity and transporter chaperoning are coupled is unknown"]},{"year":2020,"claim":"Confirmation that SARS-CoV-2 uses ACE2 as its entry receptor (with TMPRSS2-mediated priming), combined with cryo-EM structures of full-length ACE2–B0AT1 and ACE2–spike complexes, provided the molecular framework for understanding pandemic coronavirus cell entry and showed ACE2 dimerizes via its collectrin-like domain.","evidence":"Virus isolation and neutralization; pseudovirus and authentic virus entry assays with TMPRSS2 inhibitor; cryo-EM of ACE2–B0AT1 ± SARS-CoV-2 RBD at 2.9 Å; X-ray crystallography of RBD–ACE2; single-cell RNA-seq across species","pmids":["32015507","32142651","32132184","32225176","32075877","32155444","32376634","32413319"],"confidence":"High","gaps":["Mechanism by which spike binding triggers ACE2 internalization not fully resolved","Whether ACE2 enzymatic function is directly impaired during SARS-CoV-2 infection in vivo remains unclear"]},{"year":2020,"claim":"Transcriptional regulation of ACE2 was placed under epigenetic and cytokine-driven control: EZH2-mediated H3K27me3 silences ACE2, interferon signaling induces it as an ISG, and ACE2 localizes to motile cilia of upper airway epithelial cells as the initial site of viral contact.","evidence":"EZH2 knockout in hESCs with ChIP-seq; interferon stimulation with scRNA-seq; multiplexed immunofluorescence on human airway tissue","pmids":["32291076","32413319","33116139"],"confidence":"High","gaps":["Whether interferon-driven ACE2 upregulation is protective or detrimental during infection not resolved","Relative contributions of epigenetic vs. cytokine regulation in different tissues unknown"]},{"year":2021,"claim":"The PDZ scaffold NHERF1 was identified as a direct interactor that tethers ACE2 at the plasma membrane and facilitates SARS-CoV-2 internalization, establishing a host scaffolding mechanism for receptor-mediated viral entry.","evidence":"Proximity ligation assay in human lung/intestine cells, mutagenesis of PDZ motifs, pseudotyped virus entry assays","pmids":["34189428"],"confidence":"High","gaps":["Whether NHERF1 modulates ACE2 enzymatic activity is untested","Role of other PDZ-domain proteins in ACE2 membrane stabilization unknown"]},{"year":2022,"claim":"Post-translational regulation of ACE2 was mechanistically dissected: SARS-CoV-2 triggers clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2, while Nedd4-2-mediated ubiquitination at C-terminal lysines promotes proteasomal degradation relevant to neurogenic hypertension; ACE2 exists as monomers on the cell surface at low density.","evidence":"Clathrin/AP2 knockdown and lysosomal inhibitors; Nedd4-2 identification by proteomics with ACE2-5R mutagenesis and in vivo blood pressure telemetry; dSTORM super-resolution imaging of endogenous ACE2","pmids":["36287912","37161607","36971081"],"confidence":"High","gaps":["Whether other E3 ligases also target ACE2 is unexplored","How monomeric ACE2 density affects viral entry efficiency across tissues is unquantified"]},{"year":2022,"claim":"ACE2's metabolic role was expanded beyond the cardiovascular system: the ACE2/Ang-(1-7)/Mas1 axis activates PKA/Akt signaling to drive UCP1 expression and thermogenesis in brown adipose tissue, and intestinal ACE2 maintains gut barrier integrity to prevent diabetic complications including retinopathy.","evidence":"ACE2 and Mas1 knockout mice with thermogenesis phenotyping, BAT transplantation, Ang-(1-7) infusion; transgenic intestinal ACE2 overexpression in diabetic mice with ocular endpoint measurements","pmids":["35014608","36448480"],"confidence":"High","gaps":["Whether ACE2's non-angiotensin substrates contribute to metabolic phenotypes untested","Relative importance of local vs. circulating Ang-(1-7) in BAT thermogenesis unknown"]},{"year":2022,"claim":"CRISPR screens and STAT3 ChIP identified cell-type-specific transcriptional regulators of ACE2 surface abundance (including SMAD4, EP300, KDM6A, and STAT3), revealing that ACE2 expression is governed by distinct regulatory networks in different tissues.","evidence":"Genome-scale CRISPR screens in HuH7 and Calu-3 cells; ChIP and luciferase reporter assays for STAT3 at the ACE2 promoter","pmids":["35231079","35468992"],"confidence":"High","gaps":["How these regulators interact with the EZH2 epigenetic axis is uncharacterized","In vivo validation of CRISPR screen hits in primary tissues is lacking"]},{"year":2025,"claim":"Cryo-EM capture of an ACE2-induced early fusion intermediate conformation (E-FIC) of the SARS-CoV-2 spike revealed the structural mechanism by which ACE2 binding triggers the conformational cascade leading to membrane fusion, and enabled design of a dual-function antiviral targeting this intermediate.","evidence":"Cryo-EM structure of E-FIC; recombinant antiviral protein AL5E with in vitro and in vivo efficacy against ACE2-using coronaviruses","pmids":["39889696"],"confidence":"High","gaps":["Whether E-FIC is a universal intermediate across all ACE2-using coronaviruses is unconfirmed","Kinetics of E-FIC to late fusion transition on live cells not measured"]},{"year":null,"claim":"Key unresolved questions include whether SARS-CoV-2 spike binding directly impairs ACE2 catalytic activity in vivo, the physiological relevance of ACE2's non-angiotensin substrates (apelin, dynorphin) in organ-specific contexts, and how distinct transcriptional and post-translational regulatory inputs are integrated across tissues to set ACE2 surface levels.","evidence":"","pmids":[],"confidence":"Low","gaps":["No in vivo measurement of ACE2 catalytic activity during active SARS-CoV-2 infection","Apelin and dynorphin substrate cleavage not studied in knockout models","No integrated model of ACE2 transcriptional/epigenetic/post-translational regulation across cell types"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[4,12,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,19,21,24]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[19]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,6,9,23,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,12,13,14,22]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18,22]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[23,29]}],"complexes":["ACE2-B0AT1 dimer of heterodimers"],"partners":["SLC6A19","NHERF1","NEDD4L","TMPRSS2","EZH2","STAT3","SMAD4","EP300"],"other_free_text":[]},"mechanistic_narrative":"ACE2 is a zinc-dependent type I transmembrane carboxypeptidase that counterbalances the renin–angiotensin system by cleaving angiotensin II to the vasodilatory peptide Ang-(1-7) with ~400-fold higher catalytic efficiency than its conversion of angiotensin I to Ang 1-9, and also processes apelin-13 and dynorphin A 1-13 [PMID:10924499, PMID:11815627]. In vivo, ACE2 is essential for cardiac contractility, protection against acute lung injury, regulation of brown adipose thermogenesis via the Ang-(1-7)/Mas1/PKA/Akt axis, and maintenance of intestinal barrier integrity; its loss produces phenotypes rescued by concurrent ACE deletion, establishing it as the principal counter-regulatory arm of ACE [PMID:12075344, PMID:16001071, PMID:35014608, PMID:36448480]. ACE2 also serves as the obligate entry receptor for SARS-CoV and SARS-CoV-2, binding the spike receptor-binding domain through its N-terminal peptidase domain while existing predominantly as a monomer on the plasma membrane, and its surface abundance is regulated transcriptionally by EZH2-mediated H3K27me3 and STAT3, and post-translationally by Nedd4-2-dependent ubiquitination and SARS-CoV-2-induced clathrin/AP2-dependent lysosomal degradation [PMID:14647384, PMID:32132184, PMID:36971081, PMID:32291076, PMID:35468992, PMID:37161607, PMID:36287912]. Beyond the renin–angiotensin system, ACE2 chaperones the intestinal neutral amino acid transporter B0AT1 to the cell surface via its collectrin-like domain, functioning as a dimer of heterodimers [PMID:32132184, PMID:21814048]."},"prefetch_data":{"uniprot":{"accession":"Q9BYF1","full_name":"Angiotensin-converting enzyme 2","aliases":["Angiotensin-converting enzyme homolog","ACEH","Angiotensin-converting enzyme-related carboxypeptidase","ACE-related carboxypeptidase","Metalloprotease MPROT15"],"length_aa":805,"mass_kda":92.5,"function":"Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis (PubMed:27217402). Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II (PubMed:10924499, PubMed:10969042, PubMed:11815627, PubMed:14504186, PubMed:19021774). Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin (PubMed:10969042, PubMed:11815627). Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity (PubMed:18424768, PubMed:19185582) (Microbial infection) Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL63 Non-functional as a carboxypeptidase (Microbial infection) Non-functional as a receptor for human coronavirus SARS-CoV-2","subcellular_location":"Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9BYF1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACE2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACE2","total_profiled":1310},"omim":[{"mim_id":"620564","title":"ANTAGONIST OF MITOTIC EXIT NETWORK 1 HOMOLOG; AMN1","url":"https://www.omim.org/entry/620564"},{"mim_id":"613413","title":"TRANSMEMBRANE PROTEIN 106B; TMEM106B","url":"https://www.omim.org/entry/613413"},{"mim_id":"608893","title":"SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 19; SLC6A19","url":"https://www.omim.org/entry/608893"},{"mim_id":"605872","title":"C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M","url":"https://www.omim.org/entry/605872"},{"mim_id":"602060","title":"TRANSMEMBRANE SERINE PROTEASE 2; TMPRSS2","url":"https://www.omim.org/entry/602060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"gallbladder","ntpm":62.3},{"tissue":"intestine","ntpm":230.5},{"tissue":"kidney","ntpm":82.4}],"url":"https://www.proteinatlas.org/search/ACE2"},"hgnc":{"alias_symbol":["ACEH"],"prev_symbol":[]},"alphafold":{"accession":"Q9BYF1","domains":[{"cath_id":"-","chopping":"296-396","consensus_level":"medium","plddt":95.48,"start":296,"end":396},{"cath_id":"-","chopping":"615-726","consensus_level":"high","plddt":93.6729,"start":615,"end":726}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYF1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYF1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYF1-F1-predicted_aligned_error_v6.png","plddt_mean":90.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACE2","jax_strain_url":"https://www.jax.org/strain/search?query=ACE2"},"sequence":{"accession":"Q9BYF1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BYF1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BYF1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYF1"}},"corpus_meta":[{"pmid":"32660650","id":"PMC_32660650","title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.","date":"2020","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32660650","citation_count":751,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389262","id":"PMC_33389262","title":"COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection.","date":"2021","source":"European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33389262","citation_count":556,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32228252","id":"PMC_32228252","title":"COVID-19, ACE2, and the cardiovascular consequences.","date":"2020","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32228252","citation_count":518,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15671045","id":"PMC_15671045","title":"Myocardial infarction increases ACE2 expression in rat and humans.","date":"2005","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/15671045","citation_count":345,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17464936","id":"PMC_17464936","title":"The emerging role of ACE2 in physiology and disease.","date":"2007","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17464936","citation_count":339,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32582574","id":"PMC_32582574","title":"ACE2, Much More Than Just a Receptor for SARS-COV-2.","date":"2020","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32582574","citation_count":267,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27082314","id":"PMC_27082314","title":"Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.","date":"2016","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/27082314","citation_count":229,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31023337","id":"PMC_31023337","title":"ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31023337","citation_count":219,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28273875","id":"PMC_28273875","title":"Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28273875","citation_count":208,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33116139","id":"PMC_33116139","title":"ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33116139","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34782609","id":"PMC_34782609","title":"The glycosylation in SARS-CoV-2 and its receptor ACE2.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34782609","citation_count":176,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35114688","id":"PMC_35114688","title":"ACE2 binding is an ancestral and evolvable trait of sarbecoviruses.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35114688","citation_count":172,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32882331","id":"PMC_32882331","title":"Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32882331","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20134095","id":"PMC_20134095","title":"Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis.","date":"2010","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/20134095","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34478478","id":"PMC_34478478","title":"Development of ACE2 autoantibodies after SARS-CoV-2 infection.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34478478","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25664248","id":"PMC_25664248","title":"ACE and ACE2 in kidney disease.","date":"2015","source":"World journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/25664248","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36477529","id":"PMC_36477529","title":"Close relatives of MERS-CoV in bats use ACE2 as their functional receptors.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36477529","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21045683","id":"PMC_21045683","title":"ACE2: more of Ang-(1-7) or less Ang II?","date":"2011","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21045683","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33110195","id":"PMC_33110195","title":"Comparative ACE2 variation and primate COVID-19 risk.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33110195","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32364961","id":"PMC_32364961","title":"Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?","date":"2020","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32364961","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34990214","id":"PMC_34990214","title":"Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34990214","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25019157","id":"PMC_25019157","title":"ACE and ACE2 in inflammation: a tale of two enzymes.","date":"2014","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/25019157","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32374427","id":"PMC_32374427","title":"Expression of the COVID-19 receptor ACE2 in the human conjunctiva.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32374427","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32522846","id":"PMC_32522846","title":"ACE2 and COVID-19 and the resulting ARDS.","date":"2020","source":"Postgraduate medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32522846","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18768926","id":"PMC_18768926","title":"MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides.","date":"2008","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18768926","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32780149","id":"PMC_32780149","title":"Advances in research on ACE2 as a receptor for 2019-nCoV.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32780149","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31901211","id":"PMC_31901211","title":"The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases.","date":"2020","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31901211","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28413960","id":"PMC_28413960","title":"Circulating ACE2 in Cardiovascular and Kidney Diseases.","date":"2017","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28413960","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34201214","id":"PMC_34201214","title":"SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34201214","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33296619","id":"PMC_33296619","title":"Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges.","date":"2021","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33296619","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24854854","id":"PMC_24854854","title":"Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24854854","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25815211","id":"PMC_25815211","title":"The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.","date":"2015","source":"International journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/25815211","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33607284","id":"PMC_33607284","title":"Variants in ACE2; potential influences on virus infection and COVID-19 severity.","date":"2021","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33607284","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24329564","id":"PMC_24329564","title":"Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.","date":"2014","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/24329564","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33926500","id":"PMC_33926500","title":"SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33926500","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33592054","id":"PMC_33592054","title":"Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33592054","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23013041","id":"PMC_23013041","title":"The ACE2 gene: its potential as a functional candidate for cardiovascular disease.","date":"2013","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/23013041","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32956843","id":"PMC_32956843","title":"Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.","date":"2020","source":"Respiratory physiology & neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32956843","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18775121","id":"PMC_18775121","title":"Pharmacologic modulation of ACE2 expression.","date":"2008","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/18775121","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21638102","id":"PMC_21638102","title":"Role of ACE2 in diastolic and systolic heart failure.","date":"2012","source":"Heart failure reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21638102","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33836016","id":"PMC_33836016","title":"Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33836016","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33443121","id":"PMC_33443121","title":"Manipulation of ACE2 expression in COVID-19.","date":"2020","source":"Open heart","url":"https://pubmed.ncbi.nlm.nih.gov/33443121","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36287912","id":"PMC_36287912","title":"SARS-CoV-2 down-regulates ACE2 through lysosomal degradation.","date":"2022","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/36287912","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32291076","id":"PMC_32291076","title":"EZH2-mediated H3K27me3 inhibits ACE2 expression.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32291076","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33101066","id":"PMC_33101066","title":"Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33101066","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21814048","id":"PMC_21814048","title":"Collectrin and ACE2 in renal and intestinal amino acid transport.","date":"2011","source":"Channels (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21814048","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35003058","id":"PMC_35003058","title":"Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35003058","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35754059","id":"PMC_35754059","title":"SARS-CoV-2 cell entry beyond the ACE2 receptor.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35754059","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33057007","id":"PMC_33057007","title":"ACE2 mouse models: a toolbox for cardiovascular and pulmonary research.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33057007","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32818905","id":"PMC_32818905","title":"ACE2, Metformin, and COVID-19.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32818905","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36759512","id":"PMC_36759512","title":"Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36759512","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33264412","id":"PMC_33264412","title":"ACE2 in the renin-angiotensin system.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33264412","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35007846","id":"PMC_35007846","title":"Scanning the RBD-ACE2 molecular interactions in Omicron variant.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35007846","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33081670","id":"PMC_33081670","title":"Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.","date":"2021","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/33081670","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39922192","id":"PMC_39922192","title":"Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39922192","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39922191","id":"PMC_39922191","title":"Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39922191","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32974030","id":"PMC_32974030","title":"Lions, tigers and kittens too: ACE2 and susceptibility to COVID-19.","date":"2020","source":"Evolution, medicine, and public health","url":"https://pubmed.ncbi.nlm.nih.gov/32974030","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35151768","id":"PMC_35151768","title":"Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35151768","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35387486","id":"PMC_35387486","title":"Genetic Landscape of the ACE2 Coronavirus Receptor.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35387486","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33725024","id":"PMC_33725024","title":"Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33725024","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36448480","id":"PMC_36448480","title":"Maintenance of Enteral ACE2 Prevents Diabetic Retinopathy in Type 1 Diabetes.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36448480","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32469114","id":"PMC_32469114","title":"An update on ACE2 amplification and its therapeutic potential.","date":"2020","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32469114","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33052346","id":"PMC_33052346","title":"Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33052346","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34402717","id":"PMC_34402717","title":"Resveratrol supplementation reduces ACE2 expression in human adipose tissue.","date":"2021","source":"Adipocyte","url":"https://pubmed.ncbi.nlm.nih.gov/34402717","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35371596","id":"PMC_35371596","title":"ACE2 and COVID-19 Susceptibility and Severity.","date":"2022","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/35371596","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33125431","id":"PMC_33125431","title":"Kidney ACE2 expression: Implications for chronic kidney disease.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33125431","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32901821","id":"PMC_32901821","title":"Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32901821","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33275999","id":"PMC_33275999","title":"A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.","date":"2020","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33275999","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35014608","id":"PMC_35014608","title":"ACE2 pathway regulates thermogenesis and energy metabolism.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35014608","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38624559","id":"PMC_38624559","title":"COVID-19 susceptibility: potential of ACE2 polymorphisms.","date":"2020","source":"The Egyptian journal of medical human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38624559","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37161607","id":"PMC_37161607","title":"Nedd4-2 up-regulation is associated with ACE2 ubiquitination in hypertension.","date":"2023","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37161607","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21346373","id":"PMC_21346373","title":"Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis.","date":"2011","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/21346373","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34305426","id":"PMC_34305426","title":"RAAS, ACE2 and COVID-19; a mechanistic review.","date":"2021","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34305426","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34668773","id":"PMC_34668773","title":"Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/34668773","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32759311","id":"PMC_32759311","title":"Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2).","date":"2020","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32759311","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33083800","id":"PMC_33083800","title":"Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33083800","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18679036","id":"PMC_18679036","title":"Renal ACE and ACE2 expression in early diabetic rats.","date":"2008","source":"Nephron. Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/18679036","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39889696","id":"PMC_39889696","title":"Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39889696","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33723522","id":"PMC_33723522","title":"ACE2: At the crossroad of COVID-19 and lung cancer.","date":"2021","source":"Gene reports","url":"https://pubmed.ncbi.nlm.nih.gov/33723522","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35739259","id":"PMC_35739259","title":"Effect of age on human ACE2 and ACE2-expressing alveolar type II cells levels.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/35739259","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28758592","id":"PMC_28758592","title":"The Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health.","date":"2017","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/28758592","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33674876","id":"PMC_33674876","title":"Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2.","date":"2021","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/33674876","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37784209","id":"PMC_37784209","title":"Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/37784209","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35451691","id":"PMC_35451691","title":"ACE2, Circumventricular Organs and the Hypothalamus, and COVID-19.","date":"2022","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35451691","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35368365","id":"PMC_35368365","title":"Expression of ACE2 in the Intact and Acutely Injured Kidney.","date":"2021","source":"Kidney360","url":"https://pubmed.ncbi.nlm.nih.gov/35368365","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33838329","id":"PMC_33838329","title":"E-cigarette vape and lung ACE2 expression: Implications for coronavirus vulnerability.","date":"2021","source":"Environmental toxicology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33838329","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34012391","id":"PMC_34012391","title":"Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34012391","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17825789","id":"PMC_17825789","title":"Collectrin, a homologue of ACE2, its transcriptional control and functional perspectives.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17825789","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40436893","id":"PMC_40436893","title":"ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40436893","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35000261","id":"PMC_35000261","title":"ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19.","date":"2022","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35000261","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34189428","id":"PMC_34189428","title":"ACE2 interaction with cytoplasmic PDZ protein enhances SARS-CoV-2 invasion.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34189428","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33999630","id":"PMC_33999630","title":"Mechanism of Ligand Recognition by Human ACE2 Receptor.","date":"2021","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/33999630","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35468992","id":"PMC_35468992","title":"Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells.","date":"2022","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/35468992","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25182162","id":"PMC_25182162","title":"Role of collectrin, an ACE2 homologue, in blood pressure homeostasis.","date":"2014","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/25182162","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36971081","id":"PMC_36971081","title":"Coronaviruses Use ACE2 Monomers as Entry-Receptors.","date":"2023","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/36971081","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33135725","id":"PMC_33135725","title":"ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33135725","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35231079","id":"PMC_35231079","title":"Identification of cell type specific ACE2 modifiers by CRISPR screening.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35231079","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35330457","id":"PMC_35330457","title":"GSTO1, GSTO2 and ACE2 Polymorphisms Modify Susceptibility to Developing COVID-19.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35330457","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40306315","id":"PMC_40306315","title":"A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40306315","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37188812","id":"PMC_37188812","title":"Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.","date":"2023","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/37188812","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32142651","id":"PMC_32142651","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32142651","citation_count":14323,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32015507","id":"PMC_32015507","title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32015507","citation_count":13891,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32075877","id":"PMC_32075877","title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32075877","citation_count":6485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32155444","id":"PMC_32155444","title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32155444","citation_count":6362,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32225176","id":"PMC_32225176","title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32225176","citation_count":4546,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14647384","id":"PMC_14647384","title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/14647384","citation_count":4385,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15141377","id":"PMC_15141377","title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15141377","citation_count":4025,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32132184","id":"PMC_32132184","title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32132184","citation_count":3685,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32225175","id":"PMC_32225175","title":"Structural basis of receptor recognition by SARS-CoV-2.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32225175","citation_count":2752,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32376634","id":"PMC_32376634","title":"Cell entry mechanisms of SARS-CoV-2.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32376634","citation_count":2420,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10969042","id":"PMC_10969042","title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.","date":"2000","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10969042","citation_count":2338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32221306","id":"PMC_32221306","title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32221306","citation_count":2296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32094589","id":"PMC_32094589","title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.","date":"2020","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32094589","citation_count":2243,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32275855","id":"PMC_32275855","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32275855","citation_count":2225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16001071","id":"PMC_16001071","title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16001071","citation_count":1915,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32413319","id":"PMC_32413319","title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32413319","citation_count":1843,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32094336","id":"PMC_32094336","title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.","date":"2020","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/32094336","citation_count":1662,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10924499","id":"PMC_10924499","title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10924499","citation_count":1641,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32841599","id":"PMC_32841599","title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32841599","citation_count":1576,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32422645","id":"PMC_32422645","title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32422645","citation_count":1559,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23486063","id":"PMC_23486063","title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23486063","citation_count":1527,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32170560","id":"PMC_32170560","title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.","date":"2020","source":"Frontiers of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32170560","citation_count":1522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16166518","id":"PMC_16166518","title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16166518","citation_count":1486,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32454513","id":"PMC_32454513","title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32454513","citation_count":1377,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12075344","id":"PMC_12075344","title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12075344","citation_count":1367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24172901","id":"PMC_24172901","title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24172901","citation_count":1188,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32203189","id":"PMC_32203189","title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.","date":"2020","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32203189","citation_count":1164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11815627","id":"PMC_11815627","title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11815627","citation_count":1146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47225,"output_tokens":5139,"usd":0.10938},"stage2":{"model":"claude-opus-4-6","input_tokens":8727,"output_tokens":4028,"usd":0.216502},"total_usd":0.740698,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60674,"output_tokens":9136,"usd":0.159531},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13228,"output_tokens":4162,"usd":0.255285}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ACE2 is a zinc-dependent monocarboxypeptidase that cleaves angiotensin II to generate angiotensin-(1-7) and cleaves angiotensin I to generate angiotensin 1-9, functioning as a counterbalance to ACE in the renin-angiotensin system.\",\n      \"method\": \"Enzymatic activity assays, biochemical characterization\",\n      \"journal\": \"Multiple reviews citing original discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic activity established biochemically, replicated across many independent labs\",\n      \"pmids\": [\"32660650\", \"17464936\", \"21045683\", \"35151768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ACE2 serves as the functional receptor for SARS-CoV (and subsequently SARS-CoV-2) on host cells, mediating viral entry via binding of the spike glycoprotein.\",\n      \"method\": \"Pseudotype virus entry assay, binding studies, functional cell entry experiments\",\n      \"journal\": \"Multiple peer-reviewed journals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — replicated across many independent labs with multiple orthogonal methods including pseudovirus assays and structural studies\",\n      \"pmids\": [\"32660650\", \"33389262\", \"32228252\", \"17464936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ACE2 shares homology with collectrin and functions as a chaperone for the neutral amino acid transporter B0AT1 in the intestine and kidney, enabling apical expression of the transporter and amino acid absorption; mutations in this system underlie Hartnup disorder.\",\n      \"method\": \"Biochemical co-expression, functional transport assays, in vivo knockout models\",\n      \"journal\": \"The Journal of pathology; Channels (Austin, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reconstitution and in vivo genetic models across multiple labs\",\n      \"pmids\": [\"17464936\", \"20134095\", \"21814048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ACE2 protein localizes to macrophages, vascular endothelium, smooth muscle, and cardiomyocytes in the heart, and its expression increases in the border/infarct area and viable myocardium after myocardial infarction in rats and in failing human hearts.\",\n      \"method\": \"Immunohistochemistry, activity assays, in vitro autoradiography, quantitative RT-PCR\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by IHC with activity assays in rat MI model and human failing hearts\",\n      \"pmids\": [\"15671045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Angiotensin II downregulates ACE2 activity and mRNA in vascular smooth muscle cells via the MAP kinase (ERK1/2) pathway; angiotensin-(1-7) prevents this downregulation through activation of a MAP kinase phosphatase, acting through its receptor [D-Ala7]-ANG-(1-7)-sensitive receptor.\",\n      \"method\": \"In vitro cell assays, ERK1/2 activity measurements, pharmacological inhibitors (PD98059, sodium vanadate, okadaic acid), mRNA quantification\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple pharmacological tools and receptor antagonists used to dissect signaling pathway in vitro\",\n      \"pmids\": [\"18768926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 receptor protein robustly localizes within the motile cilia of airway epithelial cells in the upper (nasal) and lower (pulmonary) respiratory tracts, representing the initial subcellular site of SARS-CoV-2 viral entry; this ciliary expression is not increased by ACE inhibitors or ARBs.\",\n      \"method\": \"Immunohistochemistry with diverse panel of banked human tissue, direct subcellular localization\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment tied to functional consequence (viral entry site) with clinical medication analysis\",\n      \"pmids\": [\"33116139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EZH2-mediated H3K27me3 at the ACE2 promoter inhibits ACE2 expression; knockout of EZH2 in human embryonic stem cells leads to decreased H3K27me3 and increased H3K27ac at the ACE2 promoter and upregulation of ACE2.\",\n      \"method\": \"RNA-seq, ChIP-seq, EZH2 knockout in human embryonic stem cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and KO with defined molecular readout from single lab\",\n      \"pmids\": [\"32291076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 infection down-regulates ACE2 in vivo and in vitro by inducing clathrin- and AP2-dependent endocytosis leading to lysosomal degradation of ACE2; this down-regulation alters downstream gene expression consistent with activated cytokine signaling associated with respiratory distress.\",\n      \"method\": \"Animal model infection, cultured cell infection, mechanistic dissection with clathrin/AP2 pathway inhibitors, gene expression profiling\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo and in vitro models with mechanistic pathway dissection and downstream functional readout\",\n      \"pmids\": [\"36287912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 directly binds both PDZ domains of NHERF1 through its C-terminal PDZ-recognition motif; this interaction tethers ACE2 at the membrane and facilitates SARS-CoV-2 internalization. Disruption of the ACE2 C-terminal PDZ-binding motif decreased ACE2 membrane residence and reduced pseudotyped virus entry.\",\n      \"method\": \"Direct binding assay, proximity ligation assay in human lung and intestine cells, mutagenesis of PDZ motifs, pseudovirus entry assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding, mutagenesis, proximity ligation, and functional viral entry assay with reciprocal disruption experiments\",\n      \"pmids\": [\"34189428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nedd4-2 is an E3 ubiquitin ligase that ubiquitinates ACE2 at lysine residues in its C-terminal domain, leading to ACE2 downregulation in neurogenic hypertension; mutation of these lysine residues (ACE2-5R) produced a ubiquitination-resistant ACE2 with increased activity and resistance to Ang-II-mediated degradation.\",\n      \"method\": \"Bioinformatics, proteomics, in vitro gain/loss-of-function, mutagenesis, optogenetics, blood pressure telemetry\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutational analysis identifying modification sites, causal in vivo experiments, multiple orthogonal methods from single lab\",\n      \"pmids\": [\"37161607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 pathway (via Ang-(1-7)/Mas1 receptor) regulates thermogenesis and energy expenditure in brown adipose tissue; Ace2 and Mas1 knockout mice display impaired thermogenesis, and ACE2 pathway activation induces UCP1 and mitochondrial function via Akt/FoxO1 and PKA signaling.\",\n      \"method\": \"Knockout mouse models, brown adipose tissue transplantation, Ang-(1-7) infusion, Ace2 overexpression, mechanistic pathway analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (KO, overexpression, transplantation) with defined signaling pathway and phenotypic readouts\",\n      \"pmids\": [\"35014608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Patients with SARS-CoV-2 infection develop autoantibodies against ACE2; plasma from these patients inhibits exogenous ACE2 enzymatic activity and patients with ACE2 antibodies have lower soluble ACE2 activity in plasma.\",\n      \"method\": \"Antibody detection assays, ACE2 enzyme activity assays with fluorescent substrate, plasma inhibition assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ACE2 enzyme activity inhibition demonstrated in patient plasma, single study\",\n      \"pmids\": [\"34478478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT3 binds the ACE2 promoter and controls ACE2 expression in lung epithelial cells stimulated with IL-6; inhibition of STAT3-ACE2 promoter interaction by 6-OAP suppresses ACE2 transcription and blocks SARS-CoV-2 pseudovirus entry.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, CRISPR/pharmacological perturbation, pseudovirus entry assay\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP showing direct TF binding to ACE2 promoter with functional viral entry readout, single lab\",\n      \"pmids\": [\"35468992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR screens identified cell-type-specific regulators of ACE2 surface abundance: in liver HuH7 cells, SMAD4, EP300, PIAS1, and BAMBI regulate ACE2 at the mRNA level and influence SARS-CoV-2 susceptibility; in lung Calu-3 cells, distinct regulators including KDM6A were identified.\",\n      \"method\": \"Genome-wide CRISPR screen, individual KO validation, SARS-CoV-2 infection assay, mRNA quantification\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — high-throughput CRISPR screen with validation of individual hits and functional infection readout\",\n      \"pmids\": [\"35231079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 is a substrate for Apelin peptide degradation; apelin peptides promote ACE2 transcription and increase ACE2 protein and activity, while ACE2 in turn degrades apelin, creating a negative feedback loop between the apelin system and the ACE2/RAS axis.\",\n      \"method\": \"Enzymatic assays, transcriptional analyses, protein expression studies\",\n      \"journal\": \"Clinical science (London, England : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic and transcriptional evidence from multiple studies, but primarily review-level synthesis\",\n      \"pmids\": [\"32901821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 converts alamandine (AngA) in addition to angiotensin II to angiotensin-(1-7), functioning with multiple vasoactive substrates beyond the classical Ang II substrate.\",\n      \"method\": \"Enzymatic activity assays\",\n      \"journal\": \"Clinical and experimental pharmacology & physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic characterization, but described in review context without primary experimental detail in these abstracts\",\n      \"pmids\": [\"31901211\", \"33264412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The ACE2 D355N variant restricts spike protein-ACE2 interaction and limits SARS-CoV-2 infection both in vitro and in vivo.\",\n      \"method\": \"Genetics, biochemical binding assay, pseudovirus and live virus infection assay in vitro and in vivo\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — integrated genetics, biochemistry, and virology with in vivo validation\",\n      \"pmids\": [\"34668773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD147 regulates ACE2 surface levels; interference with CD147 function or expression alters ACE2 levels and reduces SARS-CoV-2 infection, suggesting CD147-ACE2 functional interaction at the cell surface.\",\n      \"method\": \"CD147 blocking antibody, CD147 knockdown, ACE2 expression quantification, SARS-CoV-2 infection assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function experiments with defined molecular and infectivity readouts, single study\",\n      \"pmids\": [\"34201214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Super-resolution dSTORM imaging reveals that endogenous ACE2 receptors exist as monomers in the plasma membrane at densities of only 1-2 receptors per µm²; spike protein binding does not induce ACE2 oligomerization, and a single spike protein interaction with a monomeric ACE2 is sufficient for coronavirus infection.\",\n      \"method\": \"Direct stochastic optical reconstruction microscopy (dSTORM), VSV pseudovirus infection assay, multiple labeling approaches\",\n      \"journal\": \"Angewandte Chemie (International ed. in English)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — super-resolution structural imaging with functional infection validation\",\n      \"pmids\": [\"36971081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structural analysis of NeoCoV (close MERS-CoV relative from bats) RBD-ACE2 complex revealed a distinct binding interface involving protein-glycan interactions; residues 337-342 of human ACE2 restrict NeoCoV entry, and a T510F RBD mutation enables efficient entry through human ACE2.\",\n      \"method\": \"Cryo-electron microscopy, pseudotype virus entry assay, mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with mutagenesis validation and functional entry assay\",\n      \"pmids\": [\"36477529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM captured an ACE2-induced early fusion intermediate conformation (E-FIC) of SARS-CoV-2 spike in which HR1 in S2 has ejected while S1 remains attached; this intermediate can transition to the late fusion intermediate after S2' cleavage.\",\n      \"method\": \"Cryo-electron microscopy, functional antiviral protein design targeting E-FIC\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structural determination of ACE2-induced conformational intermediate with functional validation\",\n      \"pmids\": [\"39889696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Intestinal ACE2 expression activates MasR signaling leading to GSK-3β/c-Myc-mediated decrease in intestinal glucose transporter expression, improving glucose homeostasis; maintaining intestinal ACE2 also preserves gut barrier integrity and reduces diabetic retinopathy.\",\n      \"method\": \"Genetic overexpression (Vil-Cre.hAce2KI-Akita mice), probiotic ACE2 delivery, pharmacological MasR activation, molecular pathway analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological models with defined molecular mechanism and functional readouts\",\n      \"pmids\": [\"36448480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Computational simulations reveal ACE2 samples distinct Open, Partially Open, Closed, and Fully Closed conformations; ligand binding biases the receptor toward the Closed state via a conformational selection mechanism.\",\n      \"method\": \"All-atom molecular dynamics (LiGaMD simulations), comparison with X-ray crystal structure\",\n      \"journal\": \"The journal of physical chemistry letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction validated only by consistency with existing X-ray structure, no mutagenesis or direct functional test\",\n      \"pmids\": [\"33999630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 expression in male mouse lung is sexually dimorphic and higher in males than females; ACE2 is moderately suppressible with the androgen receptor antagonist enzalutamide in male mice.\",\n      \"method\": \"Gene expression analysis in human and mouse lungs, pharmacological treatment with enzalutamide in male mice\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, expression-level findings with pharmacological manipulation but limited mechanistic follow-up\",\n      \"pmids\": [\"33083800\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ACE2 is a zinc-dependent type I transmembrane monocarboxypeptidase and ectoenzyme that counterbalances the classical renin-angiotensin system by converting angiotensin II to the vasodilatory angiotensin-(1-7) (acting via the Mas receptor) and angiotensin I to angiotensin 1-9; it also chaperones the neutral amino acid transporter B0AT1 at intestinal and renal epithelia, serves as the functional cell-surface receptor for SARS-CoV-2 and other sarbecoviruses (binding the spike RBD on motile respiratory cilia as monomers, then undergoing clathrin/AP2-mediated endocytosis and lysosomal degradation), is regulated transcriptionally by STAT3/IL-6 signaling and epigenetically by EZH2-mediated H3K27me3, is subject to ubiquitination by Nedd4-2 at its C-terminal lysines leading to proteasomal degradation in hypertension, stabilized at the membrane by interaction with the PDZ scaffold NHERF1, and regulates thermogenesis in brown adipose tissue via the Ang-(1-7)/Mas1/Akt-FoxO1/PKA-UCP1 axis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ACE2 was identified as the first human homologue of ACE; it is a zinc metalloprotease with a single HEXXH active site that functions exclusively as a carboxypeptidase, cleaving the C-terminal leucine from angiotensin I to generate angiotensin 1-9, and is not inhibited by classical ACE inhibitors (captopril, lisinopril). The gene maps to chromosome Xp22 and encodes an 805-amino-acid type I transmembrane glycoprotein secreted as a soluble form by cleavage N-terminal to the transmembrane domain.\",\n      \"method\": \"Recombinant protein expression in CHO cells, in vitro enzymatic assay, substrate cleavage characterization, northern blotting, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity with substrate characterization, independently confirmed by a second discovery paper the same year\",\n      \"pmids\": [\"10924499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ACE2 converts angiotensin I to angiotensin 1-9 and also cleaves angiotensin II; recombinant ACE2 is secreted from transfected cells by cleavage N-terminal to the transmembrane domain. ACE2 transcripts were detected specifically in heart, kidney, and testis, and immunohistochemistry localized ACE2 protein predominantly to coronary/intrarenal vascular endothelium and renal tubular epithelium.\",\n      \"method\": \"cDNA library cloning, recombinant expression, in vitro enzymatic assay, northern blot, immunohistochemistry\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity plus direct localization, foundational discovery paper\",\n      \"pmids\": [\"10969042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Comprehensive substrate profiling of purified ACE2 against 126 biological peptides revealed that ACE2 hydrolyzes angiotensin II (kcat/Km = 1.9×10⁶ M⁻¹s⁻¹), apelin-13 (kcat/Km = 2.1×10⁶ M⁻¹s⁻¹), and dynorphin A 1-13 (kcat/Km = 3.1×10⁶ M⁻¹s⁻¹) with highest efficiency; in each case only the C-terminal residue is removed. Catalytic efficiency for angiotensin II is 400-fold higher than for angiotensin I. ACE2 does not hydrolyze bradykinin.\",\n      \"method\": \"Protein purification, LC-MS substrate screening panel (126 peptides), kinetic assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro biochemical characterization with kinetic constants across broad substrate panel\",\n      \"pmids\": [\"11815627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Targeted disruption of ACE2 in mice causes severe cardiac contractility defect with increased angiotensin II levels and upregulation of hypoxia-induced genes in the heart; genetic ablation of ACE on the ACE2-null background completely rescues the cardiac phenotype, placing ACE2 functionally downstream/counter-regulatory to ACE in the renin-angiotensin system in vivo. ACE2 mRNA and protein are markedly reduced in three different rat hypertension models, and the ace2 locus maps to a hypertension QTL on the X chromosome.\",\n      \"method\": \"Knockout mouse generation, cardiac function measurements, genetic epistasis (ACE/ACE2 double knockout), QTL mapping, mRNA/protein expression in rat models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo KO with defined cardiac phenotype plus ACE/ACE2 double-KO epistasis rescue, foundational functional study\",\n      \"pmids\": [\"12075344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ACE2 was identified as the functional receptor for SARS-CoV: the S1 domain of the SARS-CoV spike protein binds ACE2 efficiently; soluble ACE2 (but not soluble ACE1) blocks S1-domain association with Vero E6 cells; 293T cells transfected with ACE2 form syncytia with S-protein-expressing cells and support SARS-CoV replication; anti-ACE2 antibody (but not anti-ACE1) blocks viral replication.\",\n      \"method\": \"Receptor identification from permissive cell lysates, transfection assay, pseudovirus/syncytia assay, antibody blockade, viral replication assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal functional assays (binding, syncytia, replication, antibody blockade), highly replicated foundational paper\",\n      \"pmids\": [\"14647384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ACE2 protein is expressed on the surface of lung alveolar epithelial cells and enterocytes of the small intestine, and in arterial/venous endothelial cells and smooth muscle cells of all organs examined, establishing tissue tropism relevant to SARS-CoV pathogenesis.\",\n      \"method\": \"Immunohistochemistry on multiple human organ samples\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein localization across multiple organs in human tissue, highly cited foundational localization study\",\n      \"pmids\": [\"15141377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ACE2 protects mice from severe acute lung injury: ACE2-deficient mice show dramatically worsened ARDS (induced by acid aspiration or sepsis), while recombinant ACE2 administration rescues lung function. The pathway involves ACE2 inactivating angiotensin II; angiotensin II acting via AT1a receptor promotes lung edema and injury, while ACE2 and AT2 receptor are protective. ACE-knockout mice show markedly improved lung injury.\",\n      \"method\": \"ACE2 knockout and recombinant ACE2 rescue in mouse ARDS models (acid aspiration, sepsis), lung function measurements, genetic epistasis with ACE KO and receptor KOs\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo KO + recombinant protein rescue + genetic epistasis across multiple models\",\n      \"pmids\": [\"16001071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ACE2 activity and mRNA increase in the border/infarct zone after myocardial infarction in rats (day 3 and day 28) and in viable myocardium by day 28; ACE2 protein localizes to macrophages, vascular endothelium, smooth muscle, and cardiomyocytes post-MI. Ramipril (ACE inhibitor) attenuates cardiac hypertrophy and inhibits ACE but does not suppress elevated ACE2 mRNA post-MI. ACE2 immunoreactivity also increases in failing human hearts.\",\n      \"method\": \"Rat MI model, quantitative RT-PCR, immunohistochemistry, in vitro autoradiography, enzymatic activity assays\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (activity assay, IHC, qPCR) in animal model plus human tissue confirmation\",\n      \"pmids\": [\"15671045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure (2.9 Å) of the SARS-CoV RBD bound to the peptidase domain of human ACE2 revealed that the RBD presents a gently concave surface cradling the N-terminal lobe of the ACE2 peptidase domain; atomic details clarify residues enabling cross-species infection and human-to-human transmission.\",\n      \"method\": \"X-ray crystallography at 2.9 Å resolution\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional annotation\",\n      \"pmids\": [\"16166518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Angiotensin II downregulates ACE2 mRNA and activity in rat vascular smooth muscle cells via the MAP kinase (ERK1/2) pathway; angiotensin-(1-7) prevents this downregulation by activating a MAP kinase phosphatase (effect blocked by tyrosine and serine-threonine phosphatase inhibitors). ANG II treatment increases ERK1/2 activity, which is reduced by ANG-(1-7) pretreatment. This MAP kinase/phosphatase axis is the primary molecular mechanism for ACE2 regulation.\",\n      \"method\": \"Cell-based assays in rat aortic VSMCs, ACE2 activity and mRNA measurement, ERK1/2 kinase assay, pharmacological inhibitors (PD98059, sodium vanadate, okadaic acid), receptor antagonist blockade\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological interventions establishing signaling pathway, mechanistically rigorous\",\n      \"pmids\": [\"18768926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ACE2 acts as an amino acid transporter chaperone: its collectrin-like domain (transmembrane domain) is required for surface expression of neutral amino acid transporter B0AT1 in the intestine, linking ACE2 to amino acid absorption and the pathogenesis of Hartnup disorder.\",\n      \"method\": \"Review synthesizing functional and genetic studies on ACE2/collectrin/B0AT1 transporter complexes in kidney and intestine\",\n      \"journal\": \"Channels (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review citing established experimental data on transporter association, consistent with structural studies\",\n      \"pmids\": [\"21814048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of full-length human ACE2 in complex with the neutral amino acid transporter B0AT1 (with and without SARS-CoV-2 RBD) at 2.9 Å resolution revealed: (1) ACE2-B0AT1 assembles as a dimer of heterodimers, with ACE2's collectrin-like domain mediating homodimerization; (2) the SARS-CoV-2 RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues.\",\n      \"method\": \"Cryo-electron microscopy at 2.9 Å overall resolution (3.5 Å at ACE2-RBD interface)\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure with direct functional validation of binding interface\",\n      \"pmids\": [\"32132184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 uses ACE2 as its entry receptor and requires TMPRSS2 for spike protein priming; a clinically approved TMPRSS2 inhibitor (camostat mesylate) blocks SARS-CoV-2 entry. Convalescent SARS-CoV-1 sera cross-neutralize SARS-CoV-2 spike-driven entry.\",\n      \"method\": \"Pseudovirus entry assay, authentic virus infection, TMPRSS2 inhibitor treatment, antibody neutralization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution assays with pseudovirus and authentic virus, pharmacological inhibition, highly replicated\",\n      \"pmids\": [\"32142651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"2019-nCoV (SARS-CoV-2) uses the same cell entry receptor ACE2 as SARS-CoV, confirmed by demonstrating that the isolated virus can be neutralized by sera from SARS patients and that the new virus shares 79.6% sequence identity with SARS-CoV.\",\n      \"method\": \"Virus isolation, whole-genome sequencing, neutralization assay with convalescent sera\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct virological characterization with neutralization confirmation\",\n      \"pmids\": [\"32015507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structure of SARS-CoV-2 RBD bound to human ACE2 peptidase domain at atomic resolution showed the overall binding mode is nearly identical to SARS-CoV RBD-ACE2, but key substitutions in SARS-CoV-2 RBD strengthen the interaction and increase ACE2-binding affinity compared to SARS-CoV.\",\n      \"method\": \"X-ray crystallography, surface plasmon resonance binding affinity measurements\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus biophysical binding measurement\",\n      \"pmids\": [\"32225176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structure of SARS-CoV-2 spike trimer demonstrated that the receptor-binding domain (RBD) binds ACE2 with higher affinity than SARS-CoV spike; in the predominant prefusion state, one of three RBDs is rotated 'up' in a receptor-accessible conformation.\",\n      \"method\": \"Cryo-EM at 3.5 Å, biolayer interferometry binding assay\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biophysical binding validation\",\n      \"pmids\": [\"32075877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 spike protein harbors a furin cleavage site at the S1/S2 boundary (absent in SARS-CoV) that is processed during biogenesis; SARS-CoV-2 S and SARS-CoV S RBDs bind human ACE2 with similar affinities. SARS-CoV polyclonal antibodies potently inhibit SARS-CoV-2 spike-mediated cell entry.\",\n      \"method\": \"Cryo-EM structure determination, cell-cell fusion assay, pseudovirus entry assay, flow cytometry binding, antibody neutralization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure plus functional entry assays\",\n      \"pmids\": [\"32155444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 RBD has higher ACE2-binding affinity than SARS-CoV RBD, but the intact SARS-CoV-2 spike has comparable or lower ACE2 affinity than SARS-CoV spike (due to less-exposed RBD). SARS-CoV-2 cell entry is pre-activated by proprotein convertase furin, reducing its dependence on target cell proteases. SARS-CoV-2 enters cells primarily through endocytosis and requires PIKfyve, TPC2, and cathepsin L.\",\n      \"method\": \"Biochemical binding assays, pseudovirus entry assays, furin inhibitor treatment, endocytosis pathway inhibitors\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple biochemical and cell-based assays with pharmacological dissection of entry pathway\",\n      \"pmids\": [\"32376634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 is an interferon-stimulated gene (ISG) in human airway epithelial cells: type I and type III interferon treatment induces ACE2 expression in vitro, and ACE2 is upregulated in vivo during viral infections. ACE2 and TMPRSS2 are co-expressed in lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.\",\n      \"method\": \"Single-cell RNA sequencing (human, NHP, mouse), in vitro interferon stimulation assays, in vivo viral infection transcriptomics\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional interferon stimulation experiment plus multi-species scRNA-seq validation\",\n      \"pmids\": [\"32413319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACE2 receptor protein robustly localizes within the motile cilia of airway epithelial cells of the upper respiratory tract, representing the likely initial subcellular site of SARS-CoV-2 entry. ACE inhibitor or ARB use does not increase ciliary ACE2 expression.\",\n      \"method\": \"Multiplexed immunofluorescence (CODEX) on banked human nasal and pulmonary tissue, immunohistochemistry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein localization by multiplexed imaging on human tissue with functional implication for viral entry\",\n      \"pmids\": [\"33116139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EZH2-mediated H3K27me3 at the ACE2 promoter region inhibits ACE2 expression: EZH2 knockout in human embryonic stem cells significantly increased ACE2 expression, ChIP-seq confirmed decreased H3K27me3 and increased H3K27ac at the ACE2 promoter upon EZH2 knockout, and reduction of H3K27me3 (but not H3K4/9/36me3) upregulated Ace2 in a mouse germ cell line.\",\n      \"method\": \"EZH2 knockout in hESCs, RNA-seq, ChIP-seq, qPCR in mouse GC-2 cells with histone methylation manipulation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus ChIP-seq chromatin mapping with orthogonal cell line validation\",\n      \"pmids\": [\"32291076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 interacts directly with the PDZ scaffold protein NHERF1 through its C-terminal PDZ-recognition motif; both NHERF1 PDZ domains bind ACE2. Disruption of NHERF1 PDZ motifs or ACE2 PDZ recognition sequence eliminates interaction. NHERF1 tethers ACE2 at the cell membrane and facilitates SARS-CoV-2 internalization: elimination of the ACE2 C-terminal PDZ-binding motif decreased ACE2 membrane residence and reduced pseudotyped virus entry.\",\n      \"method\": \"Proximity ligation assay (PLA) in human lung/intestine cells, mutagenesis of PDZ motifs, pseudotyped virus entry assay, ACE2 membrane localization quantification\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction validated by PLA at endogenous levels plus functional mutagenesis of binding interface\",\n      \"pmids\": [\"34189428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 infection down-regulates ACE2 in vivo (animal model) and in cultured cells by inducing clathrin- and AP2-dependent endocytosis leading to lysosomal degradation. ACE2 knockdown cells exhibit similar transcriptional changes to SARS-CoV-2-S-treated cells (activated cytokine signaling). A soluble ACE2 fragment with stronger SARS-CoV-2 S-binding efficiently blocks ACE2 downregulation and viral infection.\",\n      \"method\": \"In vivo infection model, cell-based endocytosis assays with clathrin/AP2 knockdown, lysosomal degradation inhibitors, ACE2 knockdown transcriptomics, pseudovirus neutralization with soluble ACE2 fragment\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection of endocytosis pathway with genetic knockdowns and pharmacological inhibitors in vivo and in vitro\",\n      \"pmids\": [\"36287912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 pathway (ACE2 cleaving Ang II to generate Ang-(1-7) acting via Mas1 receptor) is a critical regulator of thermogenesis and energy expenditure: Ace2 and Mas1 knockout mice display impaired thermogenesis; cold stimulation increases ACE2 and Ang-(1-7) in brown adipose tissue (BAT); ACE2 overexpression or Ang-(1-7) infusion ameliorates impaired thermogenesis in obese mice; mechanistically, the ACE2/Ang-(1-7)/Mas1 axis activates Akt/FoxO1 and PKA signaling, inducing UCP1 and activating mitochondrial function and white adipose browning.\",\n      \"method\": \"ACE2 and Mas1 knockout mice, BAT transplantation, ACE2 overexpression, Ang-(1-7) infusion, high-fat diet and Lepr-mutant obese models, UCP1/PKA/Akt pathway analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (KO, overexpression, BAT transplantation) with mechanistic pathway dissection\",\n      \"pmids\": [\"35014608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 endogenous receptors are present as monomers in the plasma membrane at densities of 1–2 receptors/μm², and binding of trimeric SARS-CoV-2 spike proteins does not induce ACE2 oligomerization; a single spike protein interaction with a monomeric ACE2 is sufficient for viral infection.\",\n      \"method\": \"Direct stochastic optical reconstruction microscopy (dSTORM), single-molecule localization, VSV pseudotyped virus infection assays\",\n      \"journal\": \"Angewandte Chemie (International ed. in English)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — super-resolution imaging of endogenous ACE2 with functional infection validation\",\n      \"pmids\": [\"36971081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT3 binds the ACE2 promoter and controls ACE2 expression in bronchial epithelial cells stimulated with IL-6; inhibition of STAT3-ACE2 promoter interaction by the compound 6-OAP suppresses ACE2 transcription and blocks SARS-CoV-2 pseudovirus entry into lung epithelial cells.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, qPCR, western blot, SARS-CoV-2 pseudovirus entry assay, in vivo mouse lung ACE2 measurement\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP of STAT3 at ACE2 promoter plus functional entry assay, replicated in vivo\",\n      \"pmids\": [\"35468992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nedd4-2 is the first E3 ubiquitin ligase identified to promote ACE2 ubiquitination, leading to ACE2 downregulation in neurogenic hypertension. Mutation of lysine residues in the ACE2 C-terminal domain generates a ubiquitination-resistant ACE2 (ACE2-5R) with increased activity and resistance to Ang-II-mediated degradation. Expression of ACE2-5R in the bed nucleus of the stria terminalis enhanced GABAergic input to the paraventricular nucleus and reduced hypertension, establishing ACE2's role on GABAergic neurons in sympathetic regulation.\",\n      \"method\": \"Bioinformatics + proteomics identification of E3 ligase, in vitro gain/loss-of-function, ACE2 mutagenesis (ACE2-5R), optogenetics, blood pressure telemetry, AAV-mediated brain expression, capillary western analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — proteomics-identified interaction, mutagenesis, multiple in vivo functional measurements with mechanistic pathway placement\",\n      \"pmids\": [\"37161607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A live bat SL-CoV (WIV1) closely related to SARS-CoV was isolated from bat fecal samples and demonstrated to use ACE2 from humans, civets, and Chinese horseshoe bats for cell entry, confirming ACE2 as the functional receptor for bat progenitor viruses of SARS-CoV.\",\n      \"method\": \"Virus isolation in Vero E6 cells, whole-genome sequencing, pseudovirus entry assay with ACE2 orthologs\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live virus isolation plus functional receptor usage assay with multiple ACE2 orthologs\",\n      \"pmids\": [\"24172901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACE2 inhibits breast cancer angiogenesis by suppressing the VEGFa/VEGFR2/ERK pathway: ACE2 expression in breast cancer cells downregulates VEGFa and inactivates phosphorylation of VEGFR2, MEK1/2, and ERK1/2 in endothelial cells, inhibiting tube formation, migration, and neo-angiogenesis in a zebrafish model.\",\n      \"method\": \"Transwell migration assay, tube formation assay, wound healing assay, western blot (phospho-VEGFR2/MEK/ERK), qPCR, zebrafish xenograft model\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple functional assays with pathway analysis, but single lab study\",\n      \"pmids\": [\"31023337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ACE2 maintains intestinal barrier integrity and prevents diabetic retinopathy through intestinal MasR activation: genetic overexpression of intestinal ACE2 in Akita (T1D) mice preserved gut barrier integrity, reduced systemic inflammation, improved hyperglycemia via GSK-3β/c-Myc-mediated decrease in intestinal glucose transporter expression, and delayed/reversed diabetic retinopathy.\",\n      \"method\": \"Transgenic intestinal ACE2 overexpression (Vil-Cre.hAce2KI-Akita mice), Lactobacillus-expressed ACE2 probiotic, intestinal permeability assays, ocular endpoint measurements, western blot pathway analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent genetic/pharmacological interventions with mechanistic pathway identification (MasR/GSK-3β/c-Myc)\",\n      \"pmids\": [\"36448480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Auto-antibodies against ACE2 develop in the majority (81–93%) of patients after SARS-CoV-2 infection; plasma from these patients inhibits exogenous ACE2 enzymatic activity and is associated with lower soluble ACE2 activity in plasma, consistent with autoantibody-mediated ACE2 inhibition contributing to post-acute sequelae.\",\n      \"method\": \"ELISA for ACE2 antibodies, fluorometric ACE2 enzymatic activity assay with patient plasma, soluble ACE2 protein measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct enzymatic inhibition assay with patient plasma plus ELISA, single study\",\n      \"pmids\": [\"34478478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Deep mutational scanning of all possible single amino-acid substitutions in the SARS-CoV-2 RBD identified mutations that enhance or reduce ACE2 binding affinity; most mutations are deleterious, but a subset (including at ACE2 interface residues conserved across sarbecoviruses) enhance ACE2 affinity. Constrained surface regions were identified as potential vaccine/therapeutic targets.\",\n      \"method\": \"Deep mutational scanning (yeast display), high-throughput ACE2 binding measurements across all single-amino-acid RBD variants\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with quantitative binding measurements across full RBD sequence space\",\n      \"pmids\": [\"32841599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR loss-of-function screens identified cell-type-specific regulators of ACE2 surface abundance: in HuH7 cells, SMAD4, EP300, PIAS1, and BAMBI regulate ACE2 at the mRNA level and influence SARS-CoV-2 susceptibility; in Calu-3 lung cells, KDM6A, MOGS, GPAA1, and UGP2 are distinct ACE2 modifiers, demonstrating cell-type specificity of ACE2 regulatory networks.\",\n      \"method\": \"High-throughput CRISPR screens for ACE2 surface abundance, individual KO validation, SARS-CoV-2 infection susceptibility assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-scale CRISPR screening with individual gene validation plus functional viral infection readout\",\n      \"pmids\": [\"35231079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LiGaMD simulations captured spontaneous binding/unbinding of the ACE2 inhibitor MLN-4760 and showed that unliganded ACE2 samples distinct Open, Partially Open, Closed, and Fully Closed conformations; upon ligand binding, the conformational ensemble shifts toward the Closed state (as seen in the X-ray structure), suggesting a conformational selection mechanism for ligand recognition by ACE2.\",\n      \"method\": \"All-atom ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations, microsecond timescale, validated against X-ray experimental structure\",\n      \"journal\": \"The journal of physical chemistry letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational simulation, no experimental validation of conformational states\",\n      \"pmids\": [\"33999630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM structure captured an ACE2-induced early fusion intermediate conformation (E-FIC) of SARS-CoV-2 spike in which HR1 in S2 has ejected while S1 remains attached; this E-FIC transitions to the late fusion intermediate after S2' cleavage. An E-FIC-targeted dual-functional antiviral protein (AL5E) was designed that inactivated ACE2-using coronaviruses and protected animals.\",\n      \"method\": \"Cryo-EM structure determination of ACE2-induced spike E-FIC, recombinant antiviral protein design (AL5E), in vitro and in vivo antiviral efficacy assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure of intermediate conformation with functional antiviral validation in vivo\",\n      \"pmids\": [\"39889696\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACE2 is a zinc-dependent type I transmembrane carboxypeptidase (805 aa, gene at Xp22) that constitutively degrades angiotensin II to the vasodilatory Ang-(1-7) and angiotensin I to Ang 1-9, counterbalancing ACE/angiotensin II signaling in the renin-angiotensin system; it is essential for cardiac function in vivo (loss causes contractility defects rescued by ACE deletion), protects against acute lung injury via angiotensin II inactivation, regulates thermogenesis through Ang-(1-7)/Mas1/PKA/Akt signaling in brown adipose tissue, chaperones intestinal B0AT1 amino acid transporter, is transcriptionally regulated by EZH2-mediated H3K27me3 and by STAT3, and is subject to Nedd4-2-mediated ubiquitination and proteasomal degradation, as well as SARS-CoV-2-induced clathrin/AP2-dependent lysosomal degradation; structurally, full-length ACE2 dimerizes via its collectrin-like domain and binds SARS-CoV-2 and SARS-CoV spike RBDs as monomers at the extracellular peptidase domain, making it the primary functional entry receptor for these coronaviruses, a role stabilized by interaction with the PDZ scaffold protein NHERF1 at the membrane.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ACE2 is a zinc-dependent type I transmembrane monocarboxypeptidase that serves dual roles as a key enzymatic regulator of the renin-angiotensin system and as the principal cell-surface receptor for SARS-CoV and SARS-CoV-2 entry. As an ectoenzyme, ACE2 cleaves angiotensin II to generate the vasodilatory peptide angiotensin-(1-7), which signals through the Mas receptor to regulate cardiovascular homeostasis, brown adipose thermogenesis via Akt/FoxO1/PKA-UCP1, and intestinal glucose absorption via GSK-3β/c-Myc [PMID:32660650, PMID:35014608, PMID:36448480]. ACE2 also acts as a chaperone for the neutral amino acid transporter B0AT1 at intestinal and renal epithelia [PMID:17464936]. ACE2 surface abundance is regulated by Nedd4-2-mediated ubiquitination and proteasomal degradation, NHERF1 PDZ-domain tethering at the membrane, STAT3/IL-6 and EZH2-mediated transcriptional control, and SARS-CoV-2-triggered clathrin/AP2-dependent endocytosis and lysosomal degradation; endogenous ACE2 exists as monomers on motile cilia of airway epithelia, where a single spike-ACE2 interaction suffices for viral entry [PMID:37161607, PMID:34189428, PMID:35468992, PMID:32291076, PMID:36287912, PMID:36971081, PMID:33116139].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of ACE2 as a zinc metallocarboxypeptidase that cleaves angiotensin II to angiotensin-(1-7) and angiotensin I to angiotensin 1-9 established it as a functional counterbalance to ACE in the renin-angiotensin system.\",\n      \"evidence\": \"Enzymatic activity assays and biochemical characterization, replicated across multiple labs\",\n      \"pmids\": [\"32660650\", \"17464936\", \"21045683\", \"35151768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full substrate repertoire beyond angiotensins not comprehensively mapped\", \"Relative contribution of soluble shed versus membrane-bound ACE2 to systemic RAS regulation unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that ACE2 is the functional receptor for SARS-CoV spike glycoprotein revealed an unexpected second biological role for this peptidase as a viral entry receptor, later confirmed for SARS-CoV-2.\",\n      \"evidence\": \"Pseudotype virus entry assays, spike binding studies, functional cell entry experiments\",\n      \"pmids\": [\"32660650\", \"33389262\", \"32228252\", \"17464936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enzymatic activity is relevant during viral entry\", \"Mechanism by which spike binding triggers membrane fusion not yet structurally resolved at this stage\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Localization of ACE2 to macrophages, endothelium, smooth muscle, and cardiomyocytes in the heart, with upregulation after myocardial infarction, established ACE2 as a cardioprotective enzyme relevant to heart failure.\",\n      \"evidence\": \"Immunohistochemistry and activity assays in rat MI model and human failing hearts\",\n      \"pmids\": [\"15671045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal role of ACE2 upregulation in cardiac repair versus bystander response not resolved\", \"Cell-type-specific contributions to cardioprotection not dissected\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that ACE2 chaperones B0AT1 to the apical surface of intestinal and renal epithelia revealed a non-enzymatic function in neutral amino acid transport, linking ACE2 to Hartnup disorder.\",\n      \"evidence\": \"Biochemical co-expression, functional transport assays, in vivo knockout models\",\n      \"pmids\": [\"17464936\", \"20134095\", \"21814048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of B0AT1-ACE2 interaction not yet determined at this stage\", \"Whether chaperone and enzymatic functions are coordinated or independent\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that angiotensin II downregulates ACE2 via ERK1/2 while angiotensin-(1-7) prevents this through MAP kinase phosphatase activation revealed a reciprocal feedback loop governing ACE2 expression in vascular smooth muscle.\",\n      \"evidence\": \"In vitro cell assays with pharmacological inhibitors (PD98059, sodium vanadate) and receptor antagonists\",\n      \"pmids\": [\"18768926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of this feedback loop in vascular remodeling\", \"Identity of the specific MAP kinase phosphatase involved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Localizing ACE2 specifically to motile cilia of upper and lower airway epithelial cells identified the precise subcellular site of SARS-CoV-2 initial entry and showed that ACE inhibitors/ARBs do not increase this expression.\",\n      \"evidence\": \"Immunohistochemistry across a diverse panel of banked human tissues\",\n      \"pmids\": [\"33116139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ciliary ACE2 is functionally distinct from non-ciliary ACE2 in enzymatic activity\", \"Mechanism of ACE2 trafficking to cilia\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that EZH2-mediated H3K27me3 at the ACE2 promoter silences ACE2 transcription established an epigenetic regulatory layer, where EZH2 loss switches the mark to H3K27ac and upregulates ACE2.\",\n      \"evidence\": \"RNA-seq, ChIP-seq, and EZH2 knockout in human embryonic stem cells\",\n      \"pmids\": [\"32291076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EZH2 regulation of ACE2 operates similarly in differentiated epithelial cells\", \"In vivo relevance to viral susceptibility not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of NHERF1 as a PDZ-domain scaffold that tethers ACE2 at the membrane via its C-terminal motif, and showing that disruption reduces both membrane residence and pseudovirus entry, connected ACE2 trafficking to viral susceptibility.\",\n      \"evidence\": \"Direct binding assay, proximity ligation assay in human lung/intestine cells, mutagenesis, pseudovirus entry assay\",\n      \"pmids\": [\"34189428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other PDZ-domain proteins also stabilize ACE2\", \"Impact of NHERF1-ACE2 interaction on ACE2 enzymatic function\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The ACE2 D355N natural variant was shown to restrict spike-ACE2 interaction and limit SARS-CoV-2 infection in vitro and in vivo, directly linking ACE2 genetic variation to viral susceptibility.\",\n      \"evidence\": \"Genetics, biochemical binding, pseudovirus and live virus infection assays in vitro and in vivo\",\n      \"pmids\": [\"34668773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Population frequency and clinical significance of D355N\", \"Whether D355N also affects enzymatic activity toward angiotensins\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that intestinal ACE2 activates Mas receptor signaling to decrease glucose transporter expression via GSK-3β/c-Myc, improving glucose homeostasis and reducing diabetic retinopathy, expanded ACE2's role beyond cardiovascular regulation to metabolic control.\",\n      \"evidence\": \"Genetic overexpression mice, probiotic ACE2 delivery, pharmacological MasR activation, molecular pathway analysis\",\n      \"pmids\": [\"36448480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether these metabolic effects are independent of B0AT1 chaperone function\", \"Translational relevance in human diabetes\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistic dissection showing that SARS-CoV-2 infection triggers clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2, leading to cytokine signaling dysregulation, provided a molecular basis for virus-induced ACE2 depletion in COVID-19 pathology.\",\n      \"evidence\": \"Animal model and cultured cell infection with clathrin/AP2 pathway inhibitors and gene expression profiling\",\n      \"pmids\": [\"36287912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether preventing ACE2 degradation ameliorates disease in vivo\", \"Relative contribution of shedding versus endocytic degradation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"STAT3 was identified as a transcription factor that directly binds the ACE2 promoter downstream of IL-6, linking inflammatory cytokine signaling to ACE2 transcriptional upregulation and SARS-CoV-2 susceptibility.\",\n      \"evidence\": \"ChIP assay, luciferase reporter, CRISPR/pharmacological perturbation, pseudovirus entry assay in lung epithelial cells\",\n      \"pmids\": [\"35468992\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether other STAT family members also regulate ACE2\", \"In vivo validation of STAT3 inhibition reducing viral entry\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of ACE2's role in brown adipose thermogenesis via Ang-(1-7)/Mas1/Akt-FoxO1/PKA-UCP1 signaling, using knockout and overexpression models, extended ACE2 function to energy expenditure regulation.\",\n      \"evidence\": \"Knockout mouse models (Ace2, Mas1), BAT transplantation, Ang-(1-7) infusion, Ace2 overexpression\",\n      \"pmids\": [\"35014608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ACE2 in BAT is regulated by the same mechanisms as in cardiovascular tissues\", \"Human relevance of ACE2-mediated thermogenesis\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Nedd4-2 was identified as the E3 ubiquitin ligase that ubiquitinates ACE2 C-terminal lysines for proteasomal degradation in neurogenic hypertension; a ubiquitination-resistant ACE2-5R mutant resisted Ang-II-induced degradation and retained activity, establishing post-translational degradation as a hypertension mechanism.\",\n      \"evidence\": \"Proteomics, mutagenesis of five C-terminal lysines, optogenetics, blood pressure telemetry in vivo\",\n      \"pmids\": [\"37161607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other E3 ligases also target ACE2\", \"Whether Nedd4-2-mediated degradation is tissue-specific\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Super-resolution imaging revealed that endogenous ACE2 exists as monomers at low density (~1-2/μm²) on the plasma membrane, and that spike binding does not induce oligomerization, overturning the assumption that dimeric ACE2 is required for viral entry.\",\n      \"evidence\": \"dSTORM super-resolution microscopy with multiple labeling approaches, VSV pseudovirus infection validation\",\n      \"pmids\": [\"36971081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether monomeric state applies in all cell types and tissues\", \"How low receptor density achieves efficient viral entry kinetically\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cryo-EM capture of an ACE2-induced early fusion intermediate conformation (E-FIC) of SARS-CoV-2 spike, with HR1 ejected while S1 remains attached, revealed a previously unobserved mechanistic step in ACE2-triggered viral membrane fusion.\",\n      \"evidence\": \"Cryo-EM structural determination with functional antiviral protein design targeting E-FIC\",\n      \"pmids\": [\"39889696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether E-FIC can be pharmacologically trapped in vivo to block infection\", \"Generalizability of E-FIC to other ACE2-using coronaviruses\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Outstanding questions include: (1) the structural basis for how ACE2 simultaneously serves as a peptidase, B0AT1 chaperone, and viral receptor across tissues; (2) whether tissue-specific transcriptional and post-translational regulatory mechanisms can be independently targeted; and (3) whether ACE2-directed therapies can simultaneously address cardiovascular, metabolic, and viral disease axes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integrated structural model of ACE2 multifunctionality lacking\", \"No therapeutic agent simultaneously targeting enzymatic and receptor functions\", \"In vivo tissue-specific regulatory hierarchy not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 9, 14, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 15]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1, 16, 19]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 8, 18]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 10, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 7, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 7, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [\n      \"ACE2-B0AT1\"\n    ],\n    \"partners\": [\n      \"SLC6A19\",\n      \"NHERF1\",\n      \"NEDD4L\",\n      \"MAS1\",\n      \"STAT3\",\n      \"EZH2\",\n      \"CD147\",\n      \"SMAD4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ACE2 is a zinc-dependent type I transmembrane carboxypeptidase that counterbalances the renin–angiotensin system by cleaving angiotensin II to the vasodilatory peptide Ang-(1-7) with ~400-fold higher catalytic efficiency than its conversion of angiotensin I to Ang 1-9, and also processes apelin-13 and dynorphin A 1-13 [PMID:10924499, PMID:11815627]. In vivo, ACE2 is essential for cardiac contractility, protection against acute lung injury, regulation of brown adipose thermogenesis via the Ang-(1-7)/Mas1/PKA/Akt axis, and maintenance of intestinal barrier integrity; its loss produces phenotypes rescued by concurrent ACE deletion, establishing it as the principal counter-regulatory arm of ACE [PMID:12075344, PMID:16001071, PMID:35014608, PMID:36448480]. ACE2 also serves as the obligate entry receptor for SARS-CoV and SARS-CoV-2, binding the spike receptor-binding domain through its N-terminal peptidase domain while existing predominantly as a monomer on the plasma membrane, and its surface abundance is regulated transcriptionally by EZH2-mediated H3K27me3 and STAT3, and post-translationally by Nedd4-2-dependent ubiquitination and SARS-CoV-2-induced clathrin/AP2-dependent lysosomal degradation [PMID:14647384, PMID:32132184, PMID:36971081, PMID:32291076, PMID:35468992, PMID:37161607, PMID:36287912]. Beyond the renin–angiotensin system, ACE2 chaperones the intestinal neutral amino acid transporter B0AT1 to the cell surface via its collectrin-like domain, functioning as a dimer of heterodimers [PMID:32132184, PMID:21814048].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of ACE2 as a novel carboxypeptidase homologous to ACE resolved whether a second angiotensin-converting enzyme existed and established its distinct substrate specificity and insensitivity to classical ACE inhibitors.\",\n      \"evidence\": \"Recombinant expression in CHO cells with enzymatic assays, northern blotting, and immunohistochemistry across two independent discovery papers\",\n      \"pmids\": [\"10924499\", \"10969042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role in vivo not yet determined\", \"Full substrate repertoire unknown\", \"Mechanism of ectodomain shedding uncharacterized\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Comprehensive substrate profiling and kinetic analysis revealed that ACE2 preferentially degrades angiotensin II (400-fold over Ang I), along with apelin-13 and dynorphin A, establishing it as a dedicated angiotensin II inactivator rather than a general ACE-like enzyme.\",\n      \"evidence\": \"LC-MS screening of 126 peptides with purified ACE2 and kinetic constant determination\",\n      \"pmids\": [\"11815627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of non-angiotensin substrates (apelin, dynorphin) not tested\", \"Structural basis of substrate selectivity undetermined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic ablation of ACE2 in mice demonstrated its essential role in cardiac function and placed it as the in vivo counter-regulatory enzyme to ACE, since the severe cardiac contractility defect of ACE2 knockouts was fully rescued by concurrent ACE deletion.\",\n      \"evidence\": \"ACE2 knockout mice with cardiac phenotyping, ACE/ACE2 double-knockout epistasis, QTL mapping in rat hypertension models\",\n      \"pmids\": [\"12075344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream mediators of cardiac protection not fully delineated\", \"Contribution of non-angiotensin substrates to cardiac phenotype unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The discovery that ACE2 serves as the functional receptor for SARS-CoV fundamentally expanded its biology beyond the renin–angiotensin system, showing that the viral spike S1 domain co-opts ACE2 for cell entry.\",\n      \"evidence\": \"Receptor identification from permissive cell lysates, syncytia formation, pseudovirus entry, antibody blockade, and viral replication in ACE2-transfected 293T cells\",\n      \"pmids\": [\"14647384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of spike–ACE2 interface unknown\", \"Whether ACE2 enzymatic activity is altered by spike binding not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Structural and functional studies established the atomic basis of SARS-CoV RBD–ACE2 recognition and demonstrated ACE2's protective role against acute lung injury through angiotensin II inactivation, unifying its enzymatic and receptor biology in lung pathology.\",\n      \"evidence\": \"Crystal structure of SARS-CoV RBD–ACE2 at 2.9 Å; ACE2-knockout mice with worsened ARDS rescued by recombinant ACE2 and by genetic ACE deletion\",\n      \"pmids\": [\"16166518\", \"16001071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window for recombinant ACE2 in human ARDS not defined\", \"Whether spike binding impairs ACE2 catalytic activity in vivo not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of the ERK1/2 MAP kinase pathway as the mechanism by which angiotensin II downregulates ACE2—and Ang-(1-7) opposes this via MAP kinase phosphatase activation—revealed a feedback loop governing ACE2 expression.\",\n      \"evidence\": \"Pharmacological dissection (ERK inhibitors, phosphatase inhibitors) in rat aortic VSMCs with ACE2 mRNA and activity readouts\",\n      \"pmids\": [\"18768926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific MAP kinase phosphatase not determined\", \"Relevance in human cells not confirmed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Recognition that ACE2's collectrin-like domain chaperones the neutral amino acid transporter B0AT1 to the intestinal surface linked ACE2 to amino acid absorption and Hartnup disorder, revealing a non-catalytic structural function.\",\n      \"evidence\": \"Review synthesizing functional and genetic data on ACE2/collectrin/B0AT1 transport complexes\",\n      \"pmids\": [\"21814048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural visualization of the ACE2–B0AT1 complex not yet obtained\", \"Whether ACE2 enzymatic activity and transporter chaperoning are coupled is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Confirmation that SARS-CoV-2 uses ACE2 as its entry receptor (with TMPRSS2-mediated priming), combined with cryo-EM structures of full-length ACE2–B0AT1 and ACE2–spike complexes, provided the molecular framework for understanding pandemic coronavirus cell entry and showed ACE2 dimerizes via its collectrin-like domain.\",\n      \"evidence\": \"Virus isolation and neutralization; pseudovirus and authentic virus entry assays with TMPRSS2 inhibitor; cryo-EM of ACE2–B0AT1 ± SARS-CoV-2 RBD at 2.9 Å; X-ray crystallography of RBD–ACE2; single-cell RNA-seq across species\",\n      \"pmids\": [\"32015507\", \"32142651\", \"32132184\", \"32225176\", \"32075877\", \"32155444\", \"32376634\", \"32413319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which spike binding triggers ACE2 internalization not fully resolved\", \"Whether ACE2 enzymatic function is directly impaired during SARS-CoV-2 infection in vivo remains unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Transcriptional regulation of ACE2 was placed under epigenetic and cytokine-driven control: EZH2-mediated H3K27me3 silences ACE2, interferon signaling induces it as an ISG, and ACE2 localizes to motile cilia of upper airway epithelial cells as the initial site of viral contact.\",\n      \"evidence\": \"EZH2 knockout in hESCs with ChIP-seq; interferon stimulation with scRNA-seq; multiplexed immunofluorescence on human airway tissue\",\n      \"pmids\": [\"32291076\", \"32413319\", \"33116139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether interferon-driven ACE2 upregulation is protective or detrimental during infection not resolved\", \"Relative contributions of epigenetic vs. cytokine regulation in different tissues unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The PDZ scaffold NHERF1 was identified as a direct interactor that tethers ACE2 at the plasma membrane and facilitates SARS-CoV-2 internalization, establishing a host scaffolding mechanism for receptor-mediated viral entry.\",\n      \"evidence\": \"Proximity ligation assay in human lung/intestine cells, mutagenesis of PDZ motifs, pseudotyped virus entry assays\",\n      \"pmids\": [\"34189428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NHERF1 modulates ACE2 enzymatic activity is untested\", \"Role of other PDZ-domain proteins in ACE2 membrane stabilization unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-translational regulation of ACE2 was mechanistically dissected: SARS-CoV-2 triggers clathrin/AP2-dependent endocytosis and lysosomal degradation of ACE2, while Nedd4-2-mediated ubiquitination at C-terminal lysines promotes proteasomal degradation relevant to neurogenic hypertension; ACE2 exists as monomers on the cell surface at low density.\",\n      \"evidence\": \"Clathrin/AP2 knockdown and lysosomal inhibitors; Nedd4-2 identification by proteomics with ACE2-5R mutagenesis and in vivo blood pressure telemetry; dSTORM super-resolution imaging of endogenous ACE2\",\n      \"pmids\": [\"36287912\", \"37161607\", \"36971081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other E3 ligases also target ACE2 is unexplored\", \"How monomeric ACE2 density affects viral entry efficiency across tissues is unquantified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ACE2's metabolic role was expanded beyond the cardiovascular system: the ACE2/Ang-(1-7)/Mas1 axis activates PKA/Akt signaling to drive UCP1 expression and thermogenesis in brown adipose tissue, and intestinal ACE2 maintains gut barrier integrity to prevent diabetic complications including retinopathy.\",\n      \"evidence\": \"ACE2 and Mas1 knockout mice with thermogenesis phenotyping, BAT transplantation, Ang-(1-7) infusion; transgenic intestinal ACE2 overexpression in diabetic mice with ocular endpoint measurements\",\n      \"pmids\": [\"35014608\", \"36448480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ACE2's non-angiotensin substrates contribute to metabolic phenotypes untested\", \"Relative importance of local vs. circulating Ang-(1-7) in BAT thermogenesis unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CRISPR screens and STAT3 ChIP identified cell-type-specific transcriptional regulators of ACE2 surface abundance (including SMAD4, EP300, KDM6A, and STAT3), revealing that ACE2 expression is governed by distinct regulatory networks in different tissues.\",\n      \"evidence\": \"Genome-scale CRISPR screens in HuH7 and Calu-3 cells; ChIP and luciferase reporter assays for STAT3 at the ACE2 promoter\",\n      \"pmids\": [\"35231079\", \"35468992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How these regulators interact with the EZH2 epigenetic axis is uncharacterized\", \"In vivo validation of CRISPR screen hits in primary tissues is lacking\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cryo-EM capture of an ACE2-induced early fusion intermediate conformation (E-FIC) of the SARS-CoV-2 spike revealed the structural mechanism by which ACE2 binding triggers the conformational cascade leading to membrane fusion, and enabled design of a dual-function antiviral targeting this intermediate.\",\n      \"evidence\": \"Cryo-EM structure of E-FIC; recombinant antiviral protein AL5E with in vitro and in vivo efficacy against ACE2-using coronaviruses\",\n      \"pmids\": [\"39889696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether E-FIC is a universal intermediate across all ACE2-using coronaviruses is unconfirmed\", \"Kinetics of E-FIC to late fusion transition on live cells not measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include whether SARS-CoV-2 spike binding directly impairs ACE2 catalytic activity in vivo, the physiological relevance of ACE2's non-angiotensin substrates (apelin, dynorphin) in organ-specific contexts, and how distinct transcriptional and post-translational regulatory inputs are integrated across tissues to set ACE2 surface levels.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No in vivo measurement of ACE2 catalytic activity during active SARS-CoV-2 infection\", \"Apelin and dynorphin substrate cleavage not studied in knockout models\", \"No integrated model of ACE2 transcriptional/epigenetic/post-translational regulation across cell types\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [4, 12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 19, 21, 24]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 6, 9, 23, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 12, 13, 14, 22]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 22]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [23, 29]}\n    ],\n    \"complexes\": [\n      \"ACE2-B0AT1 dimer of heterodimers\"\n    ],\n    \"partners\": [\n      \"SLC6A19\",\n      \"NHERF1\",\n      \"NEDD4L\",\n      \"TMPRSS2\",\n      \"EZH2\",\n      \"STAT3\",\n      \"SMAD4\",\n      \"EP300\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}